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Abstract 
Four mushroom and two lichen species were collected from selected forests in north-central 
British Columbia and screened for anti-proliferative and immuno-stimulatory activities. All 
species investigated were immuno-stimulatory with the strongest activity found in the hot 
water extracts of Laetiporus sp. and Phaeolepiota aurea. Anti-proliferative activity was 
primarily seen in the ethanol extracts of Laetiporus sp., P. aurea, Letharia vulpina, Vulpicida 
canadensis, and Hydnellum diabolus. Using Sevag extraction method, DEAE Sephadex 
anion-exchange and Sephacryl S-500 size-exclusion chromatography, an immuno-
stimulatory compound was purified from the hot water extract of P. aurea. The purified 
compound, made up of carbohydrate and protein, has an average molecular weight of 390 
kDa. Its carbohydrate component is rich in β-glucan. The compound can stimulate the innate 
immune system, causing a pro-inflammatory response. Additional studies are required to 
further characterize its carbohydrate and protein components in an effort to determine 
whether it is a novel immuno-stimulatory compound. 
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Chapter 1: Introduction 
1.1 A History of Mushrooms in Medicine 
Fungi comprise the second largest kingdom of eukaryotic life on this planet1. Only 
10% of the estimated 140,000 species are actually known2–4. Being rich sources of proteins, 
carbohydrates, amino acids, fatty acids, sterols, terpenoids, flavonoid compounds, vitamins 
and minerals, mushrooms have been used as food and medicine since the earliest 
civilizations2,5,6. Some of the compounds that mushrooms produce to defend themselves from 
predation and infection are what make them useful as medicine7. As well, structural 
compounds and other secondary metabolites have shown beneficial activities. The high 
diversity of fungi and the wide range of potential defensive interactions allow for a great 
array of biological responses8. As seen in Table 1, mushrooms have been used by traditional 
healers to treat a variety of ailments. 
The use of mushrooms medicinally can be tracked throughout history, and through a 
variety of cultures2. Earliest records of mushroom use come from ancient Egypt, where 
poems devoted to fungi were found in temples2. It was determined that mushrooms were 
reserved only for royalty, and no one of the lower classes could consume them without harsh 
penalty2. Greeks and Romans continued the use of fungi medicinally, importing many of 
them from Libya2. The Greek physician Hippocrates (450 BC) was said to have used Fomes 
fomentarius as an anti-inflammatory agent, and to aid in cauterizing wounds7. Even the Ice 
Man, a naturally preserved mummy from the Alps, was found with a type of birch polypore 
bound to his clothing, indicating that mushrooms were valued as early as 5300 years ago7,9. 
While some cultures, such as those from China and Japan, have maintained documented 
records of the mushrooms they use, other cultures rely on oral communications to pass on 
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knowledge2. Due to this, much knowledge of traditional mushroom medicine is not directly 
available to researchers, having been lost with the passing of cultural elders2. 
 
Table 1. Traditional uses of medicinal mushrooms. 
Scientific Name Common 
Name 
Medicinal Use References 
Calvatia 
cyathiformis 
Purple-Spored 
Puffball 
Leucorrhea, infertility, and hiccups 2,10 
Calvatia species Puff Balls Wound Healing 2,7 
Cordyceps 
militaris 
Dong Chong 
Xia Cao 
Chronic cough, asthma, hemoptysis in phthisis, 
impotence, and seminal emission 
11,12 
Daldinia 
concentrica 
Coal Fungus Upset stomach, ulcers, skin disease, whooping 
cough, and prevention of excessive growth of fetus 
2,10 
Fomes 
fomentarius 
Tinder Fungus Anti-inflammatory, and cauterizing wounds 7 
Ganoderma 
applanatum 
Artist’s Conk Antioxidant, reducing blood sugar levels, and 
antihypertensive 
2,10 
Ganoderma 
lucidum 
Reshi Chronic bronchitis, hepatitis, hypertension, 
hypercholesterolemia, immunological disorders, 
arthritis, neoplasia, and cancers 
2,10,13,14 
Ganoderma 
resinaceum 
Laquered 
Bracket 
Reduce blood sugar, and protect liver 2,10 
Grifola frondosa Maitake Spleen and stomach ailments, hemorrhoids, and to 
calm nerves and mind 
15,16 
Inonotus obliquus Chaga Worms, tuberculosis, diabetes, gastrointestinal 
cancer, cardiovascular disease, liver disease, 
stomach ailments, and as an internal cleansing agent 
17,18 
Lasiosphaera 
fenzlii 
Ma Bo Sore throat, cough and hoarseness, epistaxis and 
traumatic bleeding 
11,12 
Lentinus edodes Shiitake Tumors, influenza, heart diseases, high blood 
pressure, obesity, diabetes, liver ailments, 
respiratory diseases, exhaustion, weakness, and 
problems related to sexual dysfunction and ageing 
19 
Lentinus 
squarrosulus 
- Mumps and heart disease 2,10 
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Lignosus 
rhinocerus 
Tiger Milk 
Mushroom 
Breast cancer, fever, cough, asthma, food 
poisoning, liver cancer, chronic hepatitis, and 
gastric ulcers 
20 
Phellinus linteus Black Hoof 
Mushroom 
Detoxification, hepatoprotection, allergies, diabetes, 
oral ulcers, gastric disorders, lymphatic disease, and 
to improve blood circulation 
21 
Pleurotus tuber-
rigium 
King Tuber 
Mushroom 
Headache, cold, fever, stomach ache, and 
constipation 
2,10 
Termitomyces 
microcarpus 
- Gonorrhea, health promotor and induction of 
lactation 
2,10,22 
Termitomyces 
titanicus 
- Abdominal pain, stomach ache, ulcers, and 
constipation 
2,22 
 
Advances in biochemical techniques have allowed for the isolation and purification of 
chemical compounds. This has led to the discovery of over 150 novel enzymes, as well as 
various other compounds from mushroom sources7,23. Isolated compounds can elicit an array 
of bioactivities, including antioxidant, antimicrobial, antitumor, immunomodulatory, 
antiviral, antihyperglycemic, anti-inflammatory, cardiovascular-protective, antidiabetic, and 
hepatoprotective activities2,6,13. Due to these activities, and their low toxicity, mushroom 
products have attracted the attention of researchers in the field of drug discovery and 
development13,23,24. Since Alexander Fleming discovered penicillin, the first β-lactam 
antibiotic, from Penicillium notatum in 1928, fungi have garnered much attention from 
pharmaceutical companies as a source of novel bioactive compounds24. Due to this, many 
beneficial drugs have been discovered, allowing for advances in medical practices. For 
example, cyclosporine, an immunosuppressive drug discovered in the soil fungus 
Tolypocladium inflatum, has significantly increased survival rates in organ transplant patients 
by preventing rejection24,25. The isolation of statin compounds mevastatin (1976) and 
lovastatin (1986) from Penicillium citrinum and Monascus ruber have led to the production 
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of synthetic analogue drugs such as Lipitor®, Crestor®, and Livalo®, some of the most potent 
cholesterol-lowering agents on the market today24,26,27. Even pets have seen a benefit from 
fungus-derived drugs with the discovery of insecticidal nodulisporic acid from 
Nodulisporium sp., used as an effective flea treatment in cats and dogs24,28,29. In addition to 
being sources of novel compounds, fungi have also been utilized as bio-factories for the 
synthesis of a variety of other compounds. They are effectively used for the 
biotransformation of steroidal molecules commonly used in pharmaceutical practices24. 
Many basidiomycetes have been shown to contain biologically active polysaccharides30. 
1.2 Anticancer Activity of Medicinal Mushrooms 
Anticancer activity was first documented in mushrooms by Lucas et al. in 1957 when 
treating sarcoma-180 in mice using an extract from the fruiting body of Boletus edulis3,30. 
From this time forward, anticancer activity has been investigated in a variety of medicinal 
mushrooms (Table 2). Anticancer activity of mushroom-derived compounds has been linked 
to immunomodulatory and/or direct cytotoxic effects30–32. Isolated compounds with these 
activities include polysaccharides, polysaccharide-protein complexes, proteins, terpenes, 
lipids, and phenols32. Studies have shown that the immunomodulatory effects arise from the 
stimulation and activation of various immune cells, leading to cytokine release and 
downstream effects32. The most commonly studied, and marketed, immuno-stimulatory 
compounds found in mushrooms are β-glucans33. As they are a major component of fungal 
cell walls, it is believed that glucans are recognition molecules for fungal infections utilized 
by the immune system and, as such, are the targets of immune cell receptors such as 
complement receptor 3, dectin-1, and toll like receptors TLR-2, TLR-4, and TLR-6 32–35. 
However, the type and effectiveness of immune response is linked to the complexity of the β-
5 
 
glucan molecule, with some of the more complex polysaccharides showing more potent 
activity33. Some of the best characterized anticancer β-glucans derived from mushrooms are 
polysaccharide K (PSK), lentinan, and schizophyllan23,30,33. 
Polysaccharide-K 
Polysaccharide-K, also known as Krestin, is a protein-bound β-glucan derived from 
Trametes versicolor. The polysaccharide component consists of a (1→3)-β-glycan backbone 
with (1→6)-β-glycosidic side chains36,37. Anticancer activity of T. versicolor was first 
identified in 1965 when the remission of cancer was observed following regular consumption 
of this mushroom38. In-vitro trials showed the ability of PSK to inhibit tumor cell 
proliferation, induce apoptosis, and regulate the immune system36,38–40. Clinical trials began 
around 1970 and were found to significantly increase survival in patients with stomach, 
breast, colorectal, and esophageal cancers when used as an adjuvant to radiotherapy or 
chemotherapy41. PSK is now commercially produced in Japan for use as an adjuvant therapy 
in the treatment of breast, liver, prostate, lung, stomach, esophagus, nasopharynx, rectum, 
and colon cancer30,38. It has also been used in veterinary medicine to treat a wide array of 
animal conditions, including fibrosarcoma, adenosarcoma, mastocytoma, plasmacytoma, 
melanoma, sarcoma, and carcinoma30. This compound is orally available, spreading to the 
salivary glands, brain, liver, bone marrow, pancreas, and tumors within 24 hours of 
consumption38,40,42. Research has also identified the ability of PSK to activate dendritic cells 
and suggests that it may be useful as a vaccine adjuvant43. The immunomodulatory activity 
of PSK is suggested to involve TLR-4, where it is believed to act as a ligand to induce TNF-α 
and IL-6 inflammatory cytokines34. However, due to its broad range of activities, it is 
believed to activate multiple immunological pathways to achieve its anticancer effects44,45. 
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Lentinan 
Lentinan is obtained from the hot water extract of Lentinus edodes (Shiitake)31. It is a 
β-glucan, consisting of a (1→3)-β-glycan main chain with two (1→6)-β-D- glucopyranoside 
branches for every 5 glucose units of the backbone37,40,46. Anticancer activity was first 
documented in 1970, when researchers were able to inhibit the growth of sarcoma-180 tumor 
cells in mice31. Additional animal studies have identified its antitumor, metastasis-
preventative, and oncogenesis-preventative activities in cancers induced by chemical and 
viral agents23. Approved for pharmaceutical use in the 1980’s, lentinan was shown to 
clinically increase the survival of patients suffering from advanced gastric and colorectal 
cancers, and recurrent ovarian cancer when used as an adjuvant to conventional 
therapies23,31,47. Patients were observed to have an overall prolonged life, regression of 
tumors, and improved immune response31. By reducing debilitating symptoms such as 
nausea, pain and hair loss, lentinan used as an adjuvant therapy has been shown to improve 
the quality of life of patients undergoing chemotherapy.  It is currently used in Japan and 
China for that purpose23. It is believed that lentinan binds to scavenger receptors on myeloid 
cells33,48. 
Schizophyllan 
Schizophyllan (SPG), also known as Sizofiran, is a water-soluble exopolysaccharide 
derived from the fruiting body of Schizophyllum commune. It consists of a β-(1→3)-glucose 
backbone with single β-(1→6)-glucose side chains attached at approximately every third 
glucose backbone unit49, and is known to form a triple helical structure in water50. Its first 
documented anticancer activity was noted in 1969, when it was found to inhibit sarcoma-180 
in mice. Studies show that SPG’s antitumor activity is largely due to stimulation of a host-
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mediated immune response49,51, and is believed to be T-cell mediated52. A stimulatory effect 
on the production of IL-1, IL-2, IL-3 and IFN-γ was seen following treatment with SPG53,54. 
SPG started clinical trials in 1983, where it was found to increase the survival of patients 
with gastric, head and neck cancers55,56. As an adjuvant to radio- and chemotherapy, SPG 
was shown to increase the survival and time to recurrence of stage 2, but not stage 3, cervical 
cancer23,49. SPG is currently produced and marketed as an immunopotentiator in Japan, and 
current research is investigating its potential use as a delivery vehicle in vaccines49,57.   
1.2.1 Phellinus linteus 
Phellinus linteus has been studied for its anticancer activity via in-vitro and animal 
models. This fungus is a well-known oriental medicine, found to contain polysaccharides, 
protein complexes, and low molecular weight complexes58. Crude extracts can elicit 
immunomodulatory, as well as direct antitumor activity through apoptosis58. Phellinus linteus 
shows promise in the treatment of lung cancer59, invasive breast cancer60, benign prostatic 
hyperplasia61, and colon adenocarcinoma62; it is also able to inhibit tumor growth in mice 
inoculated with sarcoma-180 tumor cells63. Interestingly, a primarily polysaccharide extract 
of P. linteus has been seen to have a synergistic effect when used in conjunction with 
doxorubicin (a chemotherapeutic), sensitizing prostate cancer cells to the cytotoxic effects of 
this drug, activating caspase cascade leading to apoptosis64. A similar synergistic effect was 
seen when used with camptothecin (a topoisomerase inhibitor-based drug) in colon cancer 
cells65. An isolated phenol compound, Hispolon, has been shown to inhibit the growth of 
nasopharyngeal carcinoma cells, primarily through caspase activation leading to apoptosis 
through the ERK1/2, JNK1/2 and p38 MAPK patway66. As many studies still involve 
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mixtures of compounds from this mushroom, further identification and purification of those 
responsible for the observed activities is required to allow for progression into clinical trials. 
1.2.2 Ganoderma lucidum 
Another well-known Chinese medicinal mushroom is Ganoderma lucidum. Extracts 
of this mushroom are found to possess anticancer, anti-inflammatory, and antioxidant 
activity. The polysaccharide extract is known to have immunomodulating properties, while 
the triterpene fractions possess cytotoxic activity67. In-vivo studies show promise in the 
treatment of breast cancer67,68, colitis-associated cancer69, metastatic lung cancer70, and 
colorectal cancer71. Purification of select triterpenes has been performed70,72, however, 
further studies of the purified compounds are required before they are moved on to clinical 
trials. Immunomodulatory properties are believed to involve TLR-433, while cytotoxic 
activity is believed to be mediated by the mitochondria70. 
1.2.3 Other Anti-cancerous Mushrooms 
Many more mushrooms have been found to contain anti-cancerous compounds and 
these remain in various stages of study (please refer to Table 2). These include some well-
known traditionally used species such as Ganoderma lucidum, Inonotus obliquus, Lentinus 
edodes, Trametes versicolor, and more. With the increasing knowledge these studies yield, 
one must wonder how many novel compounds must exist in the unstudied species and what 
their potential may be. 
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Table 2. Some medicinal mushrooms showing anticancer activity. 
Scientific 
Name 
Common 
Name 
Cancer/Cell Line Activity References 
Amauroderma 
rude 
- Breast Cancer (MT-1, MDA-MB231, 
4T1, MDA-MB468, MCF7) 
Antitumor 
Antimetastatic 
Pro-apoptotic 
Anti-proliferative 
13 
Ganoderma 
lucidum 
Reishi Breast cancers (MDA-MD231, SUM-
149) 
Cytotoxic 
Antimetastatic 
Antitumor 
Anti-proliferative 
Immunomodulatory 
67 
Inonotus 
obliquus 
Chaga Sarcoma-198 
Human Colon Cancer (HT-29) 
Lung Carcinoma (A-549) 
Stomach Adenocarcinoma (AGS) 
Breast Adenocarcinoma (MCF-7) 
Cervical Adenocarcinoma (HeLa) 
Hepatoma (HepG2, Hep3B) 
Cytotoxic 
Pro-apoptotic 
Anti-proliferative 
73,74 
Lentinus 
edodes 
Shiitake Sarcoma-180 
Bowel Cancer 
Liver Cancer 
Stomach Cancer 
Ovarian Cancer 
Lung Cancer 
Antitumor 
Immunomodulatory 
Antimetastatic 
Anti-proliferative 
30,31,75 
Lignosus 
rhinocerus 
Tiger Milk 
Mushroom 
Human Breast Carcinoma (MCF-7) 
Human Lung Carcinoma (A549) 
Cytotoxic 
Pro-apoptotic 
Anti-proliferative 
20 
Panellus 
serotinus 
Late Fall 
Oyster 
Mushroom 
Sarcoma-180 
Colon Cancer (HT-29) 
Mouse Embryonic Fibroblast 
(NIH3T3) 
Murine Macrophage (RAW 264.7) 
Antitumor 
Immunomodulatory 
76 
Phellinus 
linteus 
Black Hoof 
Mushroom 
Lung Cancer (LNCaP) 
Breast Cancer (MDA-MB231) 
Neuroblastoma (SK-N-MC) 
Prostate Cancer (LNCaP) 
Melanoma (B16BL6) 
Benign Prostatic Hyperplasia 
Immunomodulatory 
Pro-apoptotic 
Antiangiogenic 
Antitumor 
Antimetastatic 
Anti-proliferative 
58–61 
Poria cocos Fu Ling Pancreatic Cancers (Panc-1, MiaPaca-
2, AsPc-1, BXPc-3) 
Cytotoxic 
Anti-invasive 
Pro-apoptotic 
Anti-proliferative 
77 
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Schizophyllum 
commune 
Split Gill Sarcoma-180 
Carcinomas (MM-46, MH-134) 
Bladder Tumor (BC-47) 
Fibrosarcoma (AMC-60) 
Mammary Carcinoma (A-755) 
Sarcoma-37 
Erlich Sarcoma 
Lewis lung Carcinoma 
Yoshida Sarcoma 
Stomach Cancer 
Neck Cancer 
Immunomodulatory 
Antitumor 
30,49,75 
Trametes 
versicolor 
Turkey Tail Breast Cancer 
Liver Cancer 
Prostate Cancer 
Lung Cancer 
Stomach Cancer 
Colon Cancer 
Antitumor 
Immunomodulatory 
Cytotoxic 
Pro-Apoptotic 
Anti-proliferative 
30,43,75 
 
1.3 Project Goals 
Mushrooms represent a major and largely untapped source of potentially powerful 
new pharmaceutical natural products. The fact that there are limited studies on wild 
mushrooms native to Canada, and the knowledge that many compounds derive from specific 
interactions between fungi and their host species, leads to the hypothesis that novel bioactive 
compounds can be found in British Columbia (BC) wild mushrooms. To this end, I set out to 
study some BC wild mushrooms with the goal of finding a novel compound with growth-
inhibitory or immunomodulatory activity. 
The overall goals of this study can be split into two experimental chapters. The first 
experimental chapter (Chapter 2) describes the collection and identification of 4 mushroom 
and 2 lichen species from north-central BC. This was followed by chemical extraction and 
assessment of their crude extracts for growth-inhibitory and immunomodulatory activities. 
The second experimental chapter (Chapter 3) describes the purification and characterization 
of an immuno-stimulatory compound from the hot water extract of Phaeolepiota aurea.  
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Chapter 2: Collection, Identification, and Screening of British Columbian Wild 
Mushrooms and Lichens for Anti-Proliferative and Immuno-Stimulatory Activities 
2.1 Introduction 
As indicated in the previous chapter, mushrooms contain a great variety of bioactive 
compounds with many medicinal functions8. Some of these have made their way into 
pharmaceutical practices, becoming the basis of many analogue drugs marketed today24. 
However, due to the sheer number of estimated species and lack of study, many mushroom 
species have not been characterized for their bioactive potential4. The majority of medicinal 
mushroom research has been occurring in European and Asian countries, where a history of 
traditional used has fueled interest in natural based remedies8,23. This interest has only started 
to take root in western cultures and, as such, there have been few studies focusing on 
medicinal mushrooms in North America23. 
In this chapter, I report on the identification, extraction, and bioactive screening of 
some British Columbia (BC) wild mushrooms and lichens for anti-cancerous effects: 
specifically, anti-proliferation and immuno-stimulation. Lichens and fruiting bodies of 
multiple fungal species were collected from their natural habitats throughout the BC interior 
during the Fall 2013 – Summer 2014 seasons (Table 4). Of these, 6 species (four fungi and 
two lichens) were selected for further identification and screening based upon available 
biomass and lack of previous study within the laboratory and in the general literature. Herein 
I describe the methods used in the identification, extraction, and screening of the selected 
species. I also propose which species warrant further investigation. 
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2.2 Methods 
2.2.1 Sample Collection and Identification 
Four mushroom and two lichen species were collected from throughout the BC 
interior (Table 4). Mushroom samples were tentatively identified morphologically using 
David Arora’s field guide, Mushrooms Demystified78, and Ian Gibson’s identification 
software, MatchMaker79. Lichen samples were morphologically identified using McCune’s 
guide, Macrolichens of the Pacific Northwest80. Additionally, samples were genetically 
identified using a PowerSoil DNA isolation kit (Mo Bio Laboratories, Carlsbad, USA), and 
fungal specific primers ITS3 and NLB4. These primers were selected as the internal 
transcribed spacer (ITS) region of ribosomal DNA has shown a high probability for 
successful identification in a large range of fungi1. 
 A small sample of tissue was cut from the internal flesh of the cap when the fresh 
mushroom was available. Fresh samples were stored at freezing temperatures (-20℃) until 
DNA extraction was performed, using the manufacturer protocols81. Powdered mushroom 
was also used from samples that had previously been dried. Approximately 0.25 grams of 
mushroom sample was loaded into the PowerBead Tubes, provided with the DNA isolation 
kit, and vortexed to mix. The provided Solution C1 was heated to 60℃ to dissolve 
precipitates, and 60 µL of this solution was added to each of the sample tubes, once again 
vortexing to disperse the sample within the solution. Samples were shaken for approximately 
10 minutes, to break down the tissue samples, before the tubes were loaded into a centrifuge 
and spun down at 10,000 RCF. The supernatant solution was then transferred to a clean 2 mL 
Collection Tube. Two hundred and fifty microliters of Solution C2 was then added to the 
supernatant solution and vortexed for 5 seconds. The samples were then incubated at 4℃ for 
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5 minutes to precipitate out the non-DNA materials. Sample tubes were then centrifuged at 
10,000 RCF for one minute, to pellet the non-DNA materials. The supernatant solution was 
drawn off, avoiding disruption of the pellet, and transferred again to a clean 2 mL Collection 
Tube. Two hundred microliters of Solution C3 was then added to the supernatant solution, 
and vortexed to mix. This solution was once again incubated at 4℃ for 5 minutes, then 
centrifuged at 10,000 RCF to pellet out any additional non-DNA material. The supernatant 
was drawn off and transferred to another clean 2 mL Collection Tube, avoiding the transfer 
of any pelleted material. Solution C4 was shaken to mix, and 1.2 mL was added to the 
sample tubes, vortexing for 5 seconds to mix. This solution was then loaded stepwise onto a 
Spin Filter, 675 µL at a time, and centrifuged at 10,000 RCF for 1 minute, discarding the 
flow through, until all of the solution had been filtered through. Five hundred microliters of 
Solution C5 was then loaded onto the Spin Filters and centrifuged through at 10,000 RCF for 
30 seconds. The flow through was discarded. Spin filters were once again centrifuged at 
10,000 RCF for 1 minute to remove residual solution. The spin filters were then transferred 
to a clean 2 mL Collection Tube. One hundred microliters of Solution C6 was then loaded 
onto the filter membrane of the spin columns and centrifuged at 10,000 RCF for 30 seconds. 
The spin filters were discarded and the flow through reserved as DNA solution81. 
To determine the presence of DNA in the isolated samples, 5 µL of each isolated 
sample was mixed with 2 µL of blue loading dye and run on a 1% agarose gel with a DNA 
ladder. Once the samples had run for a sufficient amount of time to allow for separation, 
approximately 45 minutes to 1 hour, the gel was photographed under UV and DNA bands 
were identified. One microliter of the isolated DNA for each sample was mixed with 29 µL 
of a provided PCR master mix containing fungal specific primers ITS3 and NLB4. These 
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samples were then thermo-cycled using the program seen in Table 3. Effectiveness of PCR 
was determined with another 1% agarose gel run of the product (Figure 3). The product of 
PCR was then cleaned using ethanol precipitation and sent for sequencing at the UNBC DNA 
sequencing facility or the Macrogen Corporation (Maryland, USA). The obtained DNA 
sequence chromatographs were loaded into sequencing software Chromas Lite82 and edited 
to remove unclear segments and correct miscalled bases. The cleaned-up sequences were 
then saved in FASTA format and loaded into NCBI’s BLAST83 to search for highly similar 
sequences (megablast). Uncultured and environmental samples were excluded from the 
search parameters. 
Table 3. Thermocycler program for PCR of isolated DNA samples. 
Step # Temperature Duration 
1 95℃ 5 minutes 
2 95℃ 1 minute 
3 52℃ 1 minute 
4 72℃ 1 minute 
5 Repeat Steps 2-4 29 repetitions 
6 72℃ 5 minutes 
7 4℃ Holding 
 
2.2.2 Chemical Extraction 
Medicinal mushroom compounds have traditionally been isolated with the use of hot 
water extraction84. While it is a simple procedure, this method may lack the ability to extract 
potentially active water-insoluble compounds. Multi-step extraction procedures have been 
developed to target a broader range of compounds. The principle behind these extractions is 
to break down the fungal cell wall, from outer to inner layers, using mild to increasingly 
stronger extraction conditions84. Mizuno developed a standard four-step extraction procedure 
that has been deemed by many to be reliable, and is often modified to suit a specific 
extraction target84,85. The extraction procedure used in this thesis is based on a modification 
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of Mizuno’s procedure85, further optimized in Dr. Lee’s lab. Mushroom specimens were 
dried at 50℃ in an oven, and then pulverized into a powder using a household blender. This 
powder was then used for chemical extraction. Stepwise extraction proceeded either 
manually (Figure 1), or with the use of a speed extractor (Figure 2). 
As described in Figure 1, the first stage of manual extraction procedures involved 
sample extraction with 80% ethanol. Powdered mushroom or lichen was loaded into a 
suitable sized flask (depending on scale of extraction) and an excess of 80% ethanol solution 
added. The flask was heated to 65℃ and held at this temperature for 3 hours with continuous 
stirring. At the end of the 3-hour ethanol extraction, the solution was suction-filtered through 
Whatman no. 2 or no. 3 filters, depending on the viscosity of the solution. The filtrate would 
then be rotary-evaporated and lyophilized. This would become Extract 1 (E1) and would be 
presumed to contain small molecules. The residue from ethanol extraction was transferred to 
a flask, and a 50% methanol extraction was then performed. Once again, the flask was heated 
to 65℃ for 3 hours with stirring. The solution was then filtered, the filtrate rotary-evaporated 
and lyophilized to become Extract 2 (E2). Once again, this fraction would be considered to 
contain low molecular weight compounds. The residue from stage 2 extraction was 
transferred to a clean flask and topped with sterile water. The flask was heated to 65℃ for 6 
hours with stirring. The solution was filtered, the filtrate rotary-evaporated and lyophilized as 
Extract 3 (E3). This fraction would be considered to contain water-soluble polysaccharides. 
The residue was transferred once more to a clean flask, and a 5% sodium hydroxide solution 
was applied as the fourth and final step of chemical extraction. The flask was heated to 65℃ 
for 6 hours with stirring, before filtering the solution and rotary-evaporating the filtrate. The 
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concentrated filtrate would then be lyophilized as Extract 4 (E4). This final fraction would be 
considered to contain water-insoluble polysaccharides. 
 
Figure 1. Flowchart outlining the manual chemical extraction procedure for obtaining crude extracts from 
mushrooms. 
 
Speed extraction used the same stepwise solvent sequence and yielded the same 
overall extracts as the manual procedure (Figure 2). Powdered mushroom or lichen was 
mixed at a 1:1 ratio with quartz sand to prevent clogging in the extraction cells. Once loaded 
onto the machine, the samples were held at a temperature of 65℃ and 100 bar pressure. For 
each solvent system, the samples were run through four cycles that consisted of sample 
saturation with the solvent and a 15-minute holding phase, followed by a 4-minute discharge 
phase where the extracts were filtered into the collection flasks. The collection flasks were 
Dried Mushroom Sample (Pulverized) 
80% Ethanol 50% Methanol 
Distilled 
Water 
5% Sodium 
Hydroxide 
65℃ for 3 Hours 
Filtered 
pH Neutralized 
Rotary-Evaporated 
Lyophilized 
Stored at 4℃ 
65℃ for 3 Hours 
Filtered 
pH Neutralized 
Rotary-Evaporated 
Lyophilized 
Stored at 4℃ 
65℃ for 6 Hours 
Filtered 
pH Neutralized 
Rotary-Evaporated 
Lyophilized 
Stored at 4℃ 
65℃ for 6 Hours 
Filtered 
pH Neutralized 
Rotary-Evaporated 
Lyophilized 
Stored at 4℃ 
Extract #1 Extract #2 Extract #3 Extract #4 
Low Molecular Weight Compounds 
Water-Soluble 
Polysaccharides 
Water-Insoluble 
Polysaccharides 
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drained and cleaned between each solvent system. The collected filtrates were pH 
neutralized, rotary-evaporated, if needed, and lyophilized to yield their respective extracts.   
 
Figure 2. Flowchart outlining the speed extractor procedure for obtaining crude extracts from 
mushrooms. Each cycle consisted of a 15-minute holding phase followed by a 4-minute discharge 
phase. 
 
2.2.3 Biological Assays for Primary Screening 
2.2.3.1 Anti-proliferation Assay 
Crude extracts were tested for their effects on cell viability against human cervical 
cancer, HeLa, cells with the use of MTT 3-(4,5-dimethyiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide assay. MTT assay is a colorimetric assay in which the tetrazolium dye, yellow in 
colour, is reduced to an insoluble formazan, purple in colour, by mitochondrial reductase in 
viable cells86. When dissolved in DMSO, the absorbance of the solution can be read on a 
spectrophotometer and the percentage of viable cells determined relative to controls. This is a 
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common in-vitro method used for determining cytotoxic or growth-inhibitory effects against 
cells86–89. 
HeLa cells were purchased from the American Type Culture Collection (Rockville, 
Maryland). Cells were grown in Eagles Minimal Essential Medium (EMEM) supplemented 
with 10% fetal bovine serum (FBS), in a 37℃ humidified incubator supplied with 5% carbon 
dioxide90. A working stock was maintained in T-25 flasks, splitting when confluent, and not 
exceeding 10-15 growth cycles to reduce the chances of mutation/differentiation within the 
culture. Working in a sterile Biosafety cabinet, the supernatant growth medium was poured 
off. Cells were then washed with 3 mL of phosphate buffered saline (PBS), before drawing it 
off and discarding it. One mL of trypsin was then added to the flask and rocked to coat the 
bottom. The flask was sealed and placed in a 37℃ incubator for approximately 3 minutes, 
until cells had detached, not exceeding 5 minutes. Addition of 9 mL of EMEM+FBS would 
then neutralize the trypsin and provide a stock solution of cells for plating. Fifty µL of this 
stock solution was aliquoted into an Eppendorf tube, and an additional 50 µL of Trypan blue 
dye mixed with it. A drop of this dyed cell solution was applied to a hemocytometer and the 
average cell count determined between 4 quadrants. This cell count was used to calculate the 
volume of stock cell solution required to prepare a plating solution of desired concentration. 
For concentration-dependent assays, a concentration of 3000 cells/well was desired. Cells 
were plated at a reduced well concentration of 2000 cells/well for time-dependent assays. 
The perimeter wells of a 96 well plate were filled with 200 µL of sterile water. The plating 
solution was then transferred to a sterile reservoir and pipetted into all remaining wells using 
a multichannel pipettor. The lid was placed on the plate, and it was incubated at 37℃ for 24 
hours before treatment with mushroom extracts. 
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Crude mushroom extracts were solubilized in a suitable solvent (water, ethanol, or 
methanol) at a concentration of 40 mg/mL. This solution was then filter sterilized into a 
sterile Eppendorf tube through a 0.2 µm syringe filter. In a sterile biological cabinet, the 
sterile solution was then used to prepare the desired treatment concentrations by dilution in 
EMEM+FBS. One-hundred µL of treatment solution was pipetted into each of its designated 
wells on the pre-incubated plate. Additionally, 100 µL of solvent control solutions were 
treated into wells respectively. Plates were sealed and incubated at 37℃ for 48 hours for 
dose-dependent assays, and for up to 7 days for time-dependent assays, treating individual 
plates with MTT every 24 hours. In time-dependent assays, day 1 plates were scanned 
untreated as the 0-hour starting point. 
MTT dye was prepared at a concentration of 5 mg/mL in PBS. This solution was 
filter sterilized through a 0.2 µm filter and stored in darkness at refrigerated temperatures 
until needed. Working in a sterile biological cabinet, the stock dye solution was diluted at a 1 
in 5 mixture with EMEM+FBS. This diluted solution was transferred to a sterile reservoir, 
and 50 µL pipetted by multichannel pipettor into each of the treated wells on the incubated 
treatment plates. These plates were then incubated at 37℃ for an additional 3 hours before 
the supernatant solution was drawn off and discarded. Care was taken as to not scrape the 
bottom of the wells with pipette tips, to avoid scraping off any cells/formazan. Two hundred 
microliters of DMSO was then pipetted into each of the treatment wells. The plate was then 
placed on a Bio-Tek Synergy 2 multi-plate reader, shaken for 5 minutes, and the absorbance 
taken at 570nm. Cell viability calculations were then performed in Excel. Significance was 
determined with the use of a student’s T-test (p=0.05). 
20 
 
2.2.3.2 Immuno-Modulatory Assay 
Enzyme linked immunosorbent assay (ELISA) is a commonly used method for 
screening immunomodulatory activity. It allows for the detection of specific cytokines 
produced in response to bioactive compounds. RAW 264.7 murine macrophage cells were 
used to screen for immunomodulatory response in the crude fractions collected from 
chemical extraction. Cells were maintained in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with glutamine and 10% FBS, in a 37℃ incubator supplied with 5% 
carbon dioxide, splitting every 2 days to prevent overgrowth and self-activation. In 
preparation of treatment, raw cells were plated at a well concentration of 100,000 cells/well 
on a 96 well plate. This was done in a similar manner to platting of HeLa cells, but with the 
use of TrypLE and serum free DMEM. The supernatant solution was poured off of a T-75 
flask of cells. Five milliliters of PBS was then added to the flask and rocked to rinse the cells. 
This solution was drawn off and discarded. One and a half milliliters of TrypLE was then 
added to the flask and rocked to coat the bottom. The flask was sealed and placed in a 37℃ 
incubator for 5-9 minutes, checking and striking the sides of the flask to dislodge adherent 
cells. Care was taken not to exceed 10 minutes as cells would become active. Once cells were 
sufficiently dislodged, 5-7 mL of serum free DMEM was added to the flask and mixed 
repeatedly via pipettor until homogenous. This would become the stock cell solution. Thirty 
microliters of the stock cell solution was mixed with 30 µL of Trypan Blue dye and applied 
to a hemocytometer. The average of four quadrant counts was determined and the volume of 
stock solution required for dilution was calculated. Once diluted, 200 µL of the cell solution 
was transferred into each well with the use of a multichannel pipette. The plates were then 
sealed and incubated at 37℃ overnight. In the morning, the supernatant medium was drawn 
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off of the cells and discarded. Wells were then washed with 300 µL of PBS. This was also 
drawn off and discarded. The wells were then topped up with 100 µL of serum free DMEM 
to prepare for treatment application. An additional 100 µL of treatment solutions, and their 
respective controls, were added to each well, leading to a final well concentration of 1 
mg/mL.  
Lipopolysaccharide (LPS) was treated at a well concentration of 500 ng/mL as a 
positive control, while serum free DMEM was used as a negative control for cell activity. 
The plates were sealed and placed in a 37℃ incubator for 6 hours. Following incubation, 180 
µL of the supernatant solution was drawn out of wells and transferred to a 96 well v-bottom 
plate. The plate was then centrifuged at 200 RCF for 10 minutes to pull down any possible 
cellular contaminants. One hundred and fifty microliters of the supernatant was then 
transferred to a 96 well plate and labelled. This plate was then sealed with parafilm and 
stored in a -80℃ freezer until ELISA was performed. 
TNF-α production was assessed with the use of a Mouse TNF (Mono/Mono) ELISA 
kit (BD Biosciences, San Diego, CA) and BD OptEIA Set Mouse TNF (BD Biosciences). 
ELISA plates were prepared as per the manufacturer protocols. One hundred microliters of 
capture antibody was plated onto a 96 well v-bottom plate, at the batch recommended 
dilution in coating buffer. The plate was sealed and incubated at 4℃ overnight. The 
following morning, wash buffer was prepared at a 1 in 20 dilution. The ELISA plate was then 
removed from refrigeration, and the capture antibody solution discarded. The plate was then 
washed 3 times with 300 µL of wash buffer, discarding between steps. The plate was then 
blocked with 200 µL of assay diluent for 1 hour at room temperature. The diluent was then 
discarded and the plate washed 3 times with 300 µL wash buffer. The plate was then treated 
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with 100 µL of cellular supernatant solution diluted in assay diluent, and TNF-α standards. 
The plate was then sealed and incubated at room temperature for 2 hours. Following 
incubation, the treatment solutions were discarded and the plate washed 5 times with 300 µL 
of wash buffer. The working detector, a solution of detection antibody and horseradish 
peroxidase diluted in assay diluent at the batch recommended dose, was then applied 100 µL 
per well. The plate was then sealed and incubated at room temperature for one hour. After 
incubation, the detector solution was discarded and the plate washed 7 times with 300 µL of 
wash buffer. Substrate solution was then prepared by mixing solutions A and B at a 1:1 ratio. 
This was then applied to the plate, 100 µL/well, and the plates wrapped in aluminum foil to 
incubate in the dark for 30 minutes. Following the 30-minute incubation, 50 µL of stop 
solution was added to the wells, turning them from blue to yellow. The plates were then 
immediately scanned on a Synergy plate reader at 450 nm and 570 nm wavelengths. The 
levels of TNF-α were then determined using PRISM 6 log-log regression analysis. 
Significance was tested with the use of a student’s T-test (p=0.05). 
2.3 Results 
2.3.1 Species Identification 
All 6 specimens were subjected to morphological and genetic identification. DNA 
isolation and PCR amplification of samples 1, 2, and 3 was successful with the use of ITS3 
and NLB4 primers. The agarose gel run of PCR products showed single bands of roughly 
500 base pairs in size, suggesting that the ITS region of fungal DNA was purified. Sample #3 
had the strongest band, suggesting a large amount of DNA had been amplified. Sample #1 
had a moderate band, suggesting slightly less DNA was retrieved from the sample. Sample 
#2 showed a weaker band, suggesting the sample may have been of lesser quality, yielding 
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less DNA product (Figure 3). DNA analysis for samples 4, 5, and 6 was performed by Dr. 
Maggie Li. A summary of identification results can be seen in Table 4. 
 
 
Figure 3. DNA analysis of PCR products. Five µL of PCR products were run on a 1% agarose gel. 
Samples 1, 2, and 3 represent specimen samples #1, #2, and #3 respectively. For the subsequent 
identification of these samples, please refer to pages 23-27. Bands can be seen around 500 base pairs, 
corresponding to the sequence length expected with fungal specific primers ITS3 and NLB4. 
24 
 
2.3.1.1 Sample #1: Hericium coralloides (Scop.: Fr) Pers. 
 
 
Hericium coralloides found growing on a cottonwood log in Cottonwood Island Park, Prince George, 
BC (September 22, 2013). 
This sample was collected from Cottonwood Island Park (Prince George, BC) on 
September 22, 2013 (see Table 4). This specimen was found growing out of dead cottonwood 
logs and stumps. Based on its unique morphology, this mushroom was identified to the genus 
Hericium, but conclusive identification of the species remained elusive due to changes in the 
classification of similar species. It was finally determined to be either H. americanum or H. 
coralloides based on morphology78,79. However, according to Ginns (1984), H. americanum 
only occurs in Eastern Canada and it does not occur on Populus; he refers the Western 
Canadian species to H. coralloides91.  
This specimen’s DNA sequences were observed to have co-amplifying sequences. 
The ITS sequence was edited to 500 bases. The NLB sequence was of poor quality and was 
thus edited to a sequence length of only 110 bases. A BLAST search was performed, and 
both sequences showed a similar hit for Hericium coralloides (Accession: AF5064591.1, % 
identity: 97% and 93%, % coverage: 100% and 100%). The NLB sequence also had a hit for 
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Clavulina cinerea (Accession: EU597083.1, % identity: 99%, % coverage: 68%), however 
this was rejected due to morphological differences. A second DNA analysis was performed 
by Dr. Maggie Li. The obtained sequences were edited to lengths of 506 bases for the ITS 
sequence, and 502 bases for the NLB sequence. Both of these sequences showed strong 
matches to H. coralloides (Accession: AF506459.1, % identity: 99% and 99%, % coverage: 
100% and 94%). The identity of this specimen was concluded to be Hericium coralloides. 
2.3.1.2 Sample #2: Hydnellum diabolus Banker 
 
Hydnellum diabolus found growing in West Twin Old Growth trail near McBride, BC. Top left 
represents aged specimen (November 5, 2013), while right and bottom show young fruiting bodies 
(September 25, 2014). 
This sample was collected from West Twin Old Growth Trail (McBride, BC) on 
November 5, 2013, based on the suggestion of Dr. Hugues Massicotte. Earlier in the season, 
this mushroom was seen to have red droplets collecting on its surface, and it was initially 
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identified as Hydnellum peckii. However, due to its late collection and waterlogged state of 
the sample specimens, they lacked defining features, being mostly dark brown in colour with 
a matted surface and debris incorporated into the fruiting bodies. A second collection was 
performed in the same location on September 25, 2014. The fresher fruiting bodies were 
found growing out of moss under damp conditions, in a cedar hemlock old growth forest. 
Mushrooms were observed to have a maroon-coloured body, lightening to the outer 
extremities, with a velvety white top. Red liquid droplets were observed on the edges and 
upper surface. The fruiting bodies were toothed, and grew in a rosette shape, incorporating 
debris such as needles, moss, and twigs. The flesh was firm but waterlogged at the time of 
collection. Keying in Arora’s field guide led to an identification of H. peckii, however 
Hydnellum diabolum (also known as H. diabolus) was also suggested to be nearly identical in 
morphology, varying only by having a hairier cap in mature specimens78. 
Initially, DNA analysis was performed on the first collection of this specimen. The 
obtained ITS sequence was of better quality than the NLB sequence, which appeared to have 
a co-amplifying sequence. Following editing, the ITS sequence consisted of 549 bases, and 
the NLB sequence 243 bases. The ITS sequence yielded hits for Hydnellum geogenium 
(Accession: AY631900.1, % identity: 99%, % coverage: 42%) and Hydnellum aurantiacum 
(Accession: AF347113.1, % identity: 98%, % coverage: 83%). The NLB sequence suggested 
multiple identities of Sarcodon imbricatus (Accession: FJ845438.1, % identity: 99%, % 
coverage: 45%), Phellodon tomentosus (Accession: FJ845424.1, % identity: 99%, % 
coverage: 45%), Hydnellum aurantiacum (Accession: KP406543.1, % identity: 99%, % 
coverage: 44%), and Hydnellum geogenium (Accession: AY631900.1, % identity: 99%, % 
coverage: 44%). Based on morphology, the Sarcodon identity was ruled out, and due to 
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colouring differences, H. aurantiacum and H. geogenium were ruled out. The identity could 
not be determined further than genus Hydnellum for the sample. A second DNA analysis was 
performed by Dr. Maggie Li, and obtained sequences were edited to lengths of 541 for the 
ITS sequence, and 532 for the NLB sequence. Both sequences showed the strongest matches 
with Hydnellum diabolus (Accession: AF351863.1, % identity: 99% and 100%, % coverage: 
40% and 48%). H. geogenium was second for both sequences (Accession: AY631900.1, % 
identity: 99% and 99%, % coverage: 41% and 33%). Due to morphological features at time 
of collection, as well as the high BLAST score, the sample was determined to be Hydnellum 
diabolus. 
2.3.1.3 Sample #3: Phaeolepiota aurea (Matt. ex Fr.) Maire 
 
Phaeolepiota aurea found growing trailside near UNBC, Prince George, BC (October 1, 2014). 
This sample was collected from the UNBC campus trails (Prince George, BC) on 
November 8, 2013. Fruiting bodies were frozen upon collection due to overnight freezing 
temperatures. Samples were observed to have a large cap, golden yellow colour, powdery 
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surface, and a large sheath on the stem. The sample was easily identified as Phaeolepiota 
aurea. This was also backed by the expert opinion of Dr. Hugues Massicotte. Additional 
collections were made from the same location in the fall seasons of 2014, 2016, and 2017. 
DNA sequences from the 2013 collection were edited to 404 bases for the ITS 
sequence, and 399 bases for the NLB sequence. Both of the sequences showed top hits for 
Phaeolepiota aurea (Accession: AM946522.1, % identity: 98% and 98%, % coverage: 75% 
and 66%).  DNA analysis of the subsequent collections was also performed, all showing 
strong hits for P. aurea with top matches between 98-100% identity (Table 4.). Based on the 
overwhelming evidence, this specimen was confidently identified as P. aurea. 
2.3.1.4 Sample #4: Laetiporus sp. 
 
Aged mushroom specimen found growing on decaying stump at Twin Falls, near Smithers, BC (May 
28, 2014). 
This sample was collected from Twin Falls (Smithers, BC) on May 28, 2014. The 
specimen was found growing off the side of a rotten stump and appeared to be aged. The 
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fruiting body was dry and had a bone like texture and was white in colour. Due to its 
degraded state, an exact identification was difficult. A matchmaker search initially yielded a 
hit for Oligoporus obductus79, however this was based on the degraded morphology. Expert 
opinion was sought, and the Laetiporus sp. complex was suggested by Dr. Keith Egger and 
Dr. Hugues Massicotte. It was believed to be an aged specimen from the previous season’s 
growth, having faded in colour and degrading with age and insect predation. Photo 
comparison, as well as description of aged specimens in Arora’s field guide78, suggested this 
to be a probable identification. 
DNA analysis was performed by Dr. Maggie Li. Obtained sequenced were edited to 
lengths of 454 bases for the ITS sequence, and 451 bases for the NLB sequence. Both 
sequences showed hits for Gibellulopsis nigrescens (Accession: KX359602.1, % identity: 95 
and 95%, % coverage: 100% and 100%), however this is a mold, suggesting the sample was 
contaminated. A second attempt at DNA analysis yielded similar results. It was determined 
that the sample was too degraded to effectively get an accurate DNA identification. Based on 
the work of Burdsall and Banik (2001), this is most likely to be L. conifericola as it is the 
only Western North American species likely to be found on conifers in this area92.  
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2.3.1.5 Sample #5: Letharia vulpina (L.) Hue 
 
Letharia vulpina growing on dead branches near Beaverdam Lake, Clinton, BC (June 23, 2014). 
This sample was collected from Beaverdam Lake (Clinton, BC) on June 23, 2014. 
The lichen was found growing on dead conifer branches. Due to its bright yellow-green 
colour and tufted appearance, this lichen was easily identified as Letharia vulpina in 
McCune’s field guide80.  
DNA analysis was performed by Dr. Maggie Li. Obtained sequences were edited to 
444 bases for the ITS sequence, and 491 bases for the NLB sequence. Sequences were 
observed to have co-amplifying sequences. A BLAST search yielded matches to Letharia 
vulpina (Accession: AF228470.1, % identity: 93%, % coverage: 75%) and Letharia sp. 
(Accession: EU543560.1, % identity: 95%, % coverage: 67%). A match for Letharia 
columbiana (Accession: KU745817.1, % identity: 95%, % coverage: 64%) was also made. 
However, based on the morphological features present, the sample identity was more likely 
to be Letharia vulpina. It is believed that the co-amplifying sequences may have caused a 
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skew in results. Based on the morphological features, this sample was concluded to be 
Letharia vulpina.  
2.3.1.6 Sample #6: Vulpicida canadensis (Räs.) J.-E. Mattsson & M. J. Lai 
 
Vulpicida canadensis growing on dead conifer branches near Beaverdam Lake, Clinton, BC (June 23, 2014). 
This lichen sample was also collected from Beaverdam Lake (Clinton, BC) on June 
23, 2014. It was found growing alongside the Letharia vulpina samples on dead conifer 
branches. Due to its distinct morphology, this sample was identified as Vulpicida canadensis 
in McCune’s field guide80. 
DNA analysis was performed by Dr. Maggie Li. The obtained ITS sequence was 
edited to 458 bases, and the NLB sequence was edited to 461 bases. Both sequences showed 
strong hits for Vulpicida canadensis (Accession: AF072238.1, % identity: 99% and 99%, % 
coverage: 71% and 61%). Based on the agreement between morphological analysis and DNA 
analysis, this sample was concluded to be Vulpicida canadensis. 
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Table 4. A summary of fungi collected in British Columbia. 
Identity Sample # Date Location in BC 
Best GenBank Match 
(%Identity/%Coverage) 
Hericium 
coralloides 1 Sept 22, 2013 
Cottonwood Island Park, 
Prince George AF506459.1 (99%/100%) 
Hydnellum 
diabolus 2 Nov 5, 2013 
West Twin Old Growth 
Trail, McBride AF351863.1 (100%/48%) 
Phaeolepiota 
aurea 3.1 Nov 8, 2013 
UNBC Campus Trails, 
Prince George AM946522.1 (98%/75%) 
Phaeolepiota 
aurea 3.2 Oct 1, 2014 
UNBC Campus Trails, 
Prince George DQ071704.2 (100%/52%) 
Phaeolepiota 
aurea 3.3 Oct 12, 2016 
UNBC Campus Trails, 
Prince George DQ071704.2 (100%/13%) 
Phaeolepiota 
aurea 3.4 Oct 13, 2017 
UNBC Campus Trails, 
Prince George DQ701704.2 (100%/35%) 
Laetiporus 
sp. 4 May 28, 2014 Twin Falls, Smithers Sample contaminated 
Letharia 
vulpina 5 June 23, 2014 Beaverdam Lake, Clinton AF228470.1 (94%/81%) 
Vulpicida 
canadensis 6 June 23, 2014 Beaverdam Lake, Clinton AF072238.1 (99%/71%) 
 
2.3.2 Chemical Extraction 
 Following identification, samples were subjected to multi-stage chemical extraction, 
yielding 4 crude extracts for each species. A combination of manual extraction (Figure 1) and 
speed extraction (Figure 2) procedures were used depending on the characteristics of the 
ground sample. While speed extraction was the quicker approach, select specimens were 
observed to clog the apparatus, leading to a shift to manual extraction. The manual 
procedures allowed for larger scaled extractions. Table 5 summarizes the results of these 
extraction procedures. 
2.3.2.1 Hericium coralloides (Scop.: Fr) Pers. 
Collected specimens were dried in an oven at 50℃. Upon pulverization, the 
powdered sample had the appearance of graham-cracker crumbs, or fine sawdust. A total of 
75.20g of powdered sample was obtained. Of this, 32.60 g (50 mL) was mixed with 50 mL of 
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quartz sand and divided equally between 3 extraction cells of the speed extractor. Extraction 
with 85% EtOH yielded an orangey-brown solution with a minor light coloured sediment 
seen settled on the bottom of the collection vials. This solution had an initial pH of 6.35, 
which was then neutralized with dropwise addition of 5% NaOH solution, bringing the final 
pH to 7.00. The sample was then rotary-evaporated, keeping the temperature below 65℃, 
and slant frozen. Lyophilization yielded a sticky, toffee-like substance (Extract #1). This 
substance was re-dissolved in 15 mL of sterile water, slant frozen, and placed back on the 
lyophilizer in an attempt to pull any residual moisture out of the sample. After 2 weeks of 
lyophilization, the sample still yielded a sweet-smelling toffee-like substance. The final mass 
was measured at 6.5718g for Extract 1 (20.15% yield). 
Sequential 50% MeOH extraction of the remaining residue from EtOH extraction 
yielded a darker brown, almost coffee-like, solution with a light coloured sediment. The 
initial pH of this solution was 6.96, which was considered close enough to neutral, and 
adjustment was not needed. The sample was rotary-evaporated, and slant frozen at -80℃ 
before being lyophilized. Lyophilized sample yielded dark sticky crystals with a sweet smell. 
This extraction yielded 3.5075g of Extract 2 (10.76% yield).  
The hot water extraction also yielded a brown tone solution. Initial pH was 6.04, 
which was adjusted to pH 6.97 with the addition of 5% NaOH. The sample was then rotary-
evaporated, slant frozen, and lyophilized. Dried sample was observed as fine brown coloured 
crystals. A total of 1.4599 g was obtained for Extract 3 (4.48% yield). 
The final extraction with 5% NaOH produced a small amount of brown coloured 
solution. This had an initial pH of 7.45, which was finally adjusted to 7.06. Due to the small 
amount collected, this sample was directly slant frozen and lyophilized. Post lyophilization, 
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the sample was light brown and had a fluffy texture. A second manual extraction was 
performed on the residue of this extraction, to try and improve yield. The mushroom sand 
mixture was combined with 800 mL of 5% NaOH and heated to 65℃ for 6 hours. The 
sample was cooled and filtered through no.2 filter paper. Upon neutralization, the solution 
was observed to precipitate. The sample was then rotary-evaporated, slant frozen and 
lyophilized. Extract 4 had a final mass of 60.64 g (186.01% yield), suggesting that the 
neutralization had added a significant amount of salt to the sample. 
2.3.2.2 Hydnellum diabolus Banker 
Dried samples were cleaned of as much debris as possible, however due to the nature 
of the fruiting bodies, it was not possible to remove all debris. Specimens were ground to a 
fine dark dust, with a total of 203.37 g of powdered mushroom obtained from the first 
collection. A 38.13g portion was mixed with 50 mL quartz sand and loaded into 2 extraction 
cells for speed extraction. A dark burgundy solution was obtained from 85% EtOH 
extraction. This solution had a pH of 6.71, which was neutralized to 7.02 with the addition of 
NaOH. The sample was rotary-evaporated, slant frozen, and lyophilized. Dried sample had 
the appearance of dark crystals. A total of 7.1589 g of sample was obtained for Extract 1 
(18.77% yield). 
Methanol extraction yielded a dark maroon coloured solution with a pH of 7.12. This 
was adjusted to 7.03 with the addition of HCl. Following concentration and lyophilization, a 
mass of 2.9824 g was obtained for Extract 2 (7.82% yield). 
Hot water extraction produced a dark solution. The initial pH was 7.18, which was 
adjusted to pH 7.04 with the addition of HCl. The sample was rotary-evaporated, slant frozen 
and lyophilized. Extract 3 yielded a recovery of 0.4848 g (1.27% yield). 
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Sodium hydroxide extraction was performed manually using the residue retrieved 
from the extraction cells of the speed extractor. The mushroom and sand mixture was topped 
up with 800 mL of 5% NaOH and heated to 65℃ with stirring for 6 hours. After 2 hours, it 
was observed that the sample had significantly thickened. It appeared that the mushroom 
particles had swelled in the solvent and appeared as gelatinous chunks in the solution. By the 
3.5-hour mark, the solution had thickened enough to hold the sand in suspension. After 6 
hours, the solution was removed from heat and allowed to cool overnight. Sample was then 
suction filtered through no. 2 filter paper, however due to the sludgy nature of the sample, the 
filter paper had to be changed multiple times during filtration. The solution was highly basic 
and it was not possible to get a steady read on the pH probe at the time. The sample was 
neutralized with the addition of HCl. Neutralized solution was then rotary-evaporated, slant 
frozen and lyophilized. A total of 27.8070 g of dried Extract 4 was obtained (72.93% yield). 
It is believed the accumulation of NaCl from pH neutralization has led to a falsely high yield. 
2.3.2.3 Phaeolepiota aurea (Matt. ex Fr.) Maire 
Upon grinding, the sample ended as a light coloured powder with the lightweight 
consistency of fine sawdust. A total of 77.68 g of sample was ground from the first collection 
of this species, with excess unprocessed specimens remaining. Fifty milliliters of powdered 
mushroom was measured out and weighed at 14.01 g. This was mixed with 50mL of quartz 
sand and distributed between 2 extraction cells for speed extraction. The first extract (85% 
EtOH) produced a clear golden-yellow solution. The initial pH of this solution was measured 
at 5.90. This was adjusted to pH 7.08 with the addition of 5% NaOH. Due to the small mass 
of sample run, a second speed extraction series was set up under similar conditions, using 
11.97 g of ground mushroom. The retrieved extract was neutralized from pH 6.72 to pH 7.01. 
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These were evaporated, slant frozen and lyophilized. A total mass of 3.0998 g was obtained 
for Extract 1 (11.93% yield). 
The second extraction with 50% MeOH also yielded a golden-yellow solution, 
however this one was opaque, with a light coloured precipitate. Initially the pH measured at 
7.43, but this was adjusted to 7.03 with the addition of HCl. The second extract was 
neutralized from pH 7.27 to pH 7.04. Neutralized solutions were rotary-evaporated and slant 
frozen. The dried samples yielded 6.2593 g of Extract 2 (24.09% yield). 
Hot water extraction was performed, yielding a golden yellow solution. Due to the 
small mass of sample run, a second speed extraction series was set up under similar 
conditions, using 11.97 g of ground mushroom. This yielded additional extracts 1, 2, and 3. 
Extract 1 was neutralized from pH 6.72 to pH 7.01, extract 2 from pH 7.27 to pH 7.04, and 
extract 3 from pH 7.18 to pH 7.04. These were evaporated, slant frozen and lyophilized. A 
combined mass of 2.3955 g was collected for Extract 3 (9.22% yield). 
Due to clogging issues on the speed extractor, the 5% NaOH extraction was 
performed manually. The residues of the prior speed extractions were combined and topped 
up with 800 mL of 5% NaOH solution. This was heated to 65℃ for 6 hours with stirring. 
The solution was allowed to cool overnight prior to suction filtration through a no 2. Filter 
paper. Upon neutralization with HCl, a precipitate was observed to have formed, most likely 
salt from the acid base reaction. The sample was rotary-evaporated, slant frozen and 
lyophilized. A final mass of 58.5043 g was obtained for Extract 4 (225.19% yield). The fact 
that this is larger than the starting mass suggests that additional compounds were produced, 
most likely NaCl during the neutralization step. 
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2.3.2.4 Laetiporus sp. 
Dried sample was pulverized, yielding a light powder with a flour like consistency. 
Fifty milliliters was measured out and weighed at 17.42 g. This was mixed with 50 mL of 
quartz sand and loaded into the extraction cells of the speed extractor. When 85% EtOH 
extraction was performed, the sample was observed to clog the extractor. Due to this, the 
residue was retrieved from the extraction cells and a manual extraction was performed. An 
additional 32.58 g of powdered mushroom was added to the retrieved residue, bringing the 
total mass of mushroom extracted to 50.00 g. This was topped up with 800 mL of 80% EtOH 
and heated to 65℃ for 3 hours with stirring. The solution was removed from heat and 
allowed to cool overnight. Suction filtration was then performed through no.2 filter paper. 
Filtrate was then neutralized with the addition of HCl, from pH 9.74 to pH 7.03. Neutralized 
sample was then rotary-evaporated, slant frozen, and lyophilized. A final mass of 0.9995 g 
was obtained for Extract 1 (2.00% yield). 
The residue retrieved from ethanol extraction was topped up with 800 mL of 50% 
MeOH and heated to 65℃ for 3 hours. Once removed from heat, the solution was left to cool 
overnight. Suction filtration was started with no.2 filter paper, however the filter paper was 
quickly clogged by the sample. The filter was then swapped for a no. 3 filter paper and left 
on suction overnight. The sample had not finished filtering by morning, and the filter was 
once again swapped for filter cloth to complete the filtration step. The filtrate was neutralized 
from pH 8.28 to pH 7.05 with HCl. The sample was then rotary-evaporated, slant frozen and 
lyophilized. A total mass of 1.2781 g was obtained post lyophilization (2.56% yield).  
The residue from the methanol extraction was combined with 800 mL of distilled 
water. The solution was heated to 65℃ for 6 hours, then left overnight to cool. An attempt 
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was made to filter through a no. 3 filter paper, but this was swapped to filter cloth due to 
clogging. The resulting filtrate solution was measured at pH 7.36 and was adjusted to pH 
7.04 with the addition of HCl. This was then rotary-evaporated, slant frozen and lyophilized. 
The retrieved mass for Extract 3 was 1.0756 g (2.15% yield). 
A final 5% NaOH extraction was performed on the residue from hot water extraction. 
Upon addition of 800 mL of 5% NaOH solution, the sample was observed to become viscous 
in solution, creating a syrup-like consistency. The solution was heated to 65℃ for 6 hours, 
and then left to cool overnight. Due to the thick nature of the solution, this sample was 
filtered through filter cloth. The resulting solution was measured at pH 13.52. Upon addition 
of concentrated HCl, the solution was observed to precipitate. At pH 12.88, the solution was 
too thick and gelatinous for the stir bar to effectively function, thus neutralization proceeded 
with manual stirring. As the solution approached pH 12.28, it had thickened significantly to 
the consistency of pudding. A smaller portion of this was taken and neutralized to a final pH 
of 6.96. This smaller portion was slant frozen directly, due to its consistency, and 
lyophilized. A 6.6570 g mass of Extract 4 was obtained from this portion, however based on 
the portion size relative to un-neutralized material, the final mass would have exceeded the 
starting mass of material, suggesting this sample also had issues with salt accumulation. 
2.3.2.5 Letharia vulpina (L.) Hue 
Collected specimens were blended to a powder with the consistency of fine lawn 
clippings. A mass of 19.20 g was mixed with 50 mL of quartz sand and loaded into the 
extraction cells of the speed extractor. Due to clogging issues within the first phase of 85% 
EtOH extraction, the run was stopped and the residue collected for manual extraction. An 
additional 30.80g of powdered lichen was added to the residue, bringing the total mass to 
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50.00g. This was topped up with 800 mL of 80% EtOH and heated to 65℃ for 3 hours. 
Sample was allowed to cool overnight and then suction filtered through a no.2 filter paper. 
Filtrate was pH adjusted from pH 3.73 to pH 7.01 with the addition of NaOH. Neutralized 
solution was rotary-evaporated, slant frozen and lyophilized. Extract 1 yielded 6.1440 g of 
product (12.3% yield). 
Residue from the prior extraction was mixed with 800 mL of 50% MeOH and heated 
to 65℃. After 3 hours, the solution was removed from heat and allowed to cool overnight. 
Upon suction filtration, the sample was observed to clog no.3 filter papers. The filter was 
then swapped for filter cloth, and filtration proceeded. Obtained filtrate had an initial pH of 
4.20, which was adjusted to pH 6.96 prior to rotary-evaporation. The concentrated sample 
was then slant frozen and lyophilized. A mass of 1.5358 g was retrieved for Extract 2 (3.07% 
yield) 
Hot water extraction was performed on the residue from methanol extraction, with the 
addition of 800 mL of distilled water. The mixture was heated to 65℃ for 6 hours, and the 
solution left to cool overnight. The sample was then filtered through filter cloth. Resulting 
solution was then neutralized from pH 3.97 to pH 6.97. The solution was then rotary-
evaporated, slant frozen and lyophilized. Hot water extraction yielded 2.0171 g of Extract 3 
(4.03% yield). 
The final extraction was performed on the residue from hot water extraction. A volume of 
800 mL of 5% NaOH solution was added to the residue and heated to 65℃ for 6 hours. The 
solution was left to cool and then suction filtered through filter cloth, yielding a filtrate of pH 
13.59. This was neutralized to pH 7.05 with the addition of concentrated HCl. The sample 
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was rotary-evaporated, slant frozen and lyophilized. Dried sample was weighed at 70.3828 g 
(140.77% yield), suggesting Extract 4 contained a significant amount of salt. 
2.3.2.6 Vulpicida canadensis (Räs.) J.-E. Mattsson & M. J. Lai 
Dried sample was ground in a blender to a yellow-green powder. A mass of 50.02 g 
was weighed out and topped up with 800 mL of 80% EtOH solution. The sample was heated 
to 65℃ for 3 hours, then removed from heat and allowed to cool overnight. The cooled 
solution was suction filtered through no. 2 filter paper. The filtrate was neutralized from pH 
4.80 to pH 7.01 with the addition of 5% NaOH solution. The sample was then rotary-
evaporated, slant frozen, and lyophilized. Dried sample obtained had a mass of 4.2083 g 
(8.41% yield).  
The residue of ethanol extraction was combined with 800 mL of 50% MeOH. This 
was heated to 65℃ for 3 hours and left to cool overnight. Suction filtration was attempted 
through no.2 and no. 3 filter papers, but ultimately had to be done through filtration cloth due 
to clogging issues. The filtrate was neutralized from pH 4.66 to pH 6.99. This was then 
rotary-evaporated, slant frozen and lyophilized. The final Extract 2 sample had a mass of 
2.6061 g (5.21% yield). 
The residue from methanol extraction was mixed with 800 mL of distilled water and 
heated to 65℃ for 6 hours. Upon cooling, the solution was filtered through filtration cloth. 
The filtrate was then neutralized with the addition of 5% NaOH solution, from pH 4.47 to pH 
7.05. Neutralized sample was then rotary-evaporated, slant frozen and lyophilized. Extract 3 
had a mass of 2.5622 g once dried (5.12% yield). 
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The hot water residue was then extracted with sodium hydroxide. The mushroom 
sample was topped up with 800 mL of 5% NaOH and heated to 65℃ for 6 hours. The 
resulting solution was left to cool overnight. The solution was then filtered through filtration 
cloth. Filtrate solution was measured to have a pH of 13.64, which was then neutralized to 
pH 7.05 with the addition of HCl. The sample was then rotary-evaporated, slant frozen and 
lyophilized. The final mass retrieved was 68.1114 g of Extract 4 (136.17% yield). This 
sample is believed to contain significant amounts of salt. 
42 
 
Table 5. Summary of chemical extraction results. (* yields from NaOH extractions were falsely high due to the 
production of NaCl during pH neutralization) 
Fungal 
Sample 
Starting 
Material 
(g) 
Extract 
Solvent 
Extraction 
Method 
Recovered 
Mass (g) 
% Yield 
Hericium 
coralloides 
32.60 85% EtOH Speed 6.5718 20.15% 
50% MeOH Speed 3.5075 10.76% 
Hot Water Speed 1.4599 4.48% 
5% NaOH Speed/Manual 60.64 *186.01% 
Hydnellum 
diabolus 
38.13 85% EtOH Speed 7.1589 18.77% 
50% MeOH Speed 2.9824 7.82% 
Hot Water Speed 0.4848 1.27% 
5% NaOH Manual 27.807 *72.93% 
Phaeolepiota 
aurea 
25.98 85% EtOH Speed 3.0998 11.93% 
50% MeOH Speed 6.2593 24.09% 
Hot Water Speed 2.3955 9.22% 
5% NaOH Manual 58.5043 *225.19% 
Laetiporus sp. 50.00 80% EtOH Manual 0.9995 2.00% 
50% MeOH Manual 1.2781 2.56% 
Hot Water Manual 1.0756 2.15% 
5% NaOH Manual *N/A *N/A 
Letharia 
vulpina 
50.00 80% EtOH Manual 6.1440 12.30% 
50% MeOH Manual 1.5358 3.07% 
Hot Water Manual 2.0171 4.03% 
5% NaOH Manual 70.3828 *140.77% 
Vulpicida 
canadensis 
50.02 80% EtOH Manual 4.2083 8.41% 
50% MeOH Manual 2.6061 5.21% 
Hot Water Manual 2.5622 5.12% 
5% NaOH Manual 68.1114 *136.17% 
 
2.3.3 Cell Viability MTT Assay  
Crude extracts were tested against HeLa cells for growth-inhibitory activity. While 
water was preferred, crude extracts were spot tested for solubility in various solvents. Crude 
extracts were ultimately dissolved in water or methanol at a concentration of 20 mg/mL to 
produce a stock solution for dose-dependent assays. A 40 mg/mL stock solution 
concentration was adopted for time-dependent assays to reduce the amount of solvent 
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introduced into wells. These solutions were pH neutralized and filter sterilized through a 0.2 
µm syringe filter prior to being diluted and applied to cells. HeLa cells were plated at a well 
concentration of 3000 cells/well for dose-dependent assays. In these, multiple concentrations 
were tested against cells to determine the effectiveness of the extracts to inhibit cell growth, 
as well at what dose they became effective at. Based on the results of dose-dependent assays, 
select extracts were chosen to proceed with time-dependent assays. HeLa cells were plated at 
a lower well concentration of 2000 cells/well for inhibitory extracts, and 1500 cells/well for 
extracts that showed stimulatory effects. Significance was tested with the use of a student T-
test (p=0.05). 
2.3.3.1 Hericium coralloides (Scop.: Fr) Pers. 
As shown in Figure 4, all extracts from H. coralloides did not appear to have any 
growth-inhibitory activity. Extracts 2 and 3 appeared to stimulate HeLa cell growth, showing 
significant deviation from the control at 0.5 mg/mL and 1.0 mg/mL, with a max stimulation 
of 128% and 134% respectively. Extract 1 was also observed to have modest growth-
stimulatory activity at the same concentrations, showing a maximum stimulation of 108% at 
1.0 mg/mL. Extract 4 only affected cells at 0.5 mg/mL, increasing growth by 114%, however 
this effect was not carried through at higher doses, dropping back to normal growth (Figure 
4). 
Due to the stimulatory effects seen in the first 3 extracts, these were selected to 
proceed into time-dependent MTT assay experiments. Initially, the crude extracts were tested 
at a dose of 0.5 mg/mL. However, these were not observed to significantly alter cell growth 
at any time points during the 7-day assay (Figure 5). A second time-dependent assay was 
performed, this time at a higher dose of 1.0 mg/mL. During the seven-day assay, Extract 1 
44 
 
was not observed to stimulate or inhibit cell growth. Extract 2 deviated from the control on 
day 3 and day 7, falling short of the growth of control cells. Extract 3 was seen to stimulate 
over days 5 and 6, but ultimately the control cells had caught up with growth by day 7 
(Figure 6). Since the extracts were not able to consistently stimulate or inhibit cells during 
the 7-day period, it is concluded that H. coralloides had no significant effect on the growth of 
HeLa cells. 
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Figure 4. Dose-dependent MTT-assay of H. coralloides crude extracts. HeLa cells were plated at a 
density of 3000 cells/well. Treatment was applied at well concentrations of 0.01, 0.5, 0.1 0.5, and 1.0 
mg/mL for 48 hours prior to MTT application. Cell viability was standardized against the solvent 
control (H2O). Error bars reflect the standard error of the mean (SEM). 
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Figure 5. Time-dependent MTT-assay of H. coralloides crude extracts. Cells were plated at a density 
of 1500 cells/well and were treated with crude extracts at 0.5 mg/mL. Cell viability was tested against 
the day 7 control (H2O). Error bars are SEM. 
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Figure 6. Time-dependent MTT-assay of H. coralloides crude extracts. Cells were plated at a density 
of 1500 cells/well and were treated with crude extracts at 1.0 mg/mL. Cell viability was tested against 
the day 7 control (H2O). Error bars reflect SEM. 
 
2.3.3.2 Hydnellum diabolus Banker 
Growth-inhibitory activity was observed in the crude extracts of H. diabolus. The 
strongest inhibition was observed with Extract 2, dropping cell viability to 70.8% when 
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treated at 0.5 mg/mL, and 26.2% at 1.0 mg/mL. Close behind this was Extract 1, which again 
showed significant activity at concentrations greater than 0.5 mg/mL, dropping cell viability 
by up to 31.9%. Extract 3 showed less inhibition, deviating from the control at 0.5 and 1.0 
mg/mL, reducing cell growth to only 51.2% of the control. The final extract was only 
effective at the higher dose, reducing cell viability to 88.9% in treatments of 1.0 mg/mL 
(Figure 7). 
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Figure 7. Dose-dependent MTT-assay of H. diabolus crude extracts. HeLa cells were plated at a 
density of 3000 cells/well. Treatments were applied at well concentrations of 0.01, 0.05, 0.1, 0.5, and 
1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against the solvent 
control (H2O). Error bars reflect SEM. 
 
Based on the dose-dependent results, extracts 1 and 3 were selected as candidates for 
time-dependent assay. Both were initially treated at a concentration of 0.75 mg/mL, as this 
was roughly where 50% inhibition was seen in the dose-dependent graph. Both extracts were 
observed to significantly decrease cell viability within 24 hours of treatment. Extract 3 
dropped cell viability to 3.69% at the 24-hour mark, and the cells were never able to recover, 
finishing at 2.93% viability on day 7. Extract 1 also dropped viability to 11.6% within 24 
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hours, again holding the cells at this low value for the duration of the assay, finishing at 
9.77% viability on day 7 (Figure 8). A second lower dose run was set up, this time treating 
cells with only 0.1 mg/mL of extracts 1 and 3. Cells were less affected by the lower dose, 
with only extract 3 significantly inhibiting growth in days 3-6. However, inhibition was not 
significant on day 7, suggesting the cells had recovered. Extract 1 did not deviate from 
normal cell growth until day 6, whereby it was observed to stimulate cell growth, finishing at 
118% of the control at day 7 (Figure 9). In conclusion, these results show that extracts 1 and 
3 of H. diabolus are growth-inhibitory at higher concentrations. 
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Figure 8. Time-dependent MTT assay of growth-inhibitory extracts from H. diabolus. HeLa cells were 
plated at 2000 cells/well and treated with 0.75 mg/mL of crude extracts. Cell viability was tested 
against the day 7 control (H2O). Error bars reflect SEM. 
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Figure 9. Time-dependent MTT-assay of crude extracts isolated from H. diabolus. HeLa cells were 
plated at a density of 2000 cells/well and treated with crude extracts at 0.1 mg/mL. Cell viability was 
determined against the day 7 solvent control (H2O). Error bars reflect SEM. 
 
2.3.3.3 Phaeolepiota aurea (Matt. ex Fr.) Maire 
Dose-dependent assay showed both stimulatory and strong inhibitory activity in P. 
aurea extracts. Extract 1 showed strong inhibition, deviating from the control at 
concentrations as low as 0.05 mg/mL. Maximum inhibition was seen at 1.0 mg/mL, with cell 
viability dropping to 8.27%. Extract 2 showed mild inhibition throughout all concentrations, 
however it appeared irregular, dropping to a cell viability of 75.9% at doses of 0.1 mg/mL 
before rising back up to 90.7% viability at dose of 1.0 mg/mL. Mild inhibition was also seen 
at all concentrations in extract 4, which showed a gradual decline in viability to 65.7% at 1.0 
mg/mL treatment. Extract 3 was observed to be stimulatory, starting with a decline to 72.9% 
in 0.05 mg/mL treatments before jumping up to a final stimulation of 135% in 1.0 mg/mL 
treatments (Figure 10). 
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Figure 10. Dose-dependent MTT-assay of P. aurea crude extracts. HeLa cells were plated at a density 
of 3000 cells/well. Treatment was applied at well concentrations of 0.01, 0.5, 0.1 0.5, and 1.0 mg/mL 
for 48 hours prior to MTT application. Cell viability was standardized against the solvent controls (E1: 
MeOH, E2: H2O, E3: H2O, E4: H2O). Error bars reflect the SEM. 
 
Due to their stronger effects, extracts 1 and 3 were selected to proceed into time-
dependent assays. Extract 1 was initially treated at a dose of 0.5 mg/mL and was observed to 
show significant inhibition within 24 hours of treatment. Viability was only 13.1% at 24 
hours, and subsequently dropped to only 2.57% at the end of the assay (Figure 11). A second 
lower dose run was performed, treating the cells with only 0.1 mg/mL of extract 1. Again, a 
significant decline in cells was observed at the 24-hour mark. Viability remained lower for 
the subsequent days, until day 7, whereby the deviation was no longer significant. This 
suggests that the cells were able to overcome the effects of the lower dose treatment within 
144 hours (Figure 12). Extract 3 was treated at a dose of 0.5 mg/mL to determine its 
stimulatory effect over time. While significant activity was observed within 24 hours, it was 
growth-inhibitory instead of stimulatory. By day 7, treated cells were at 65.4% of the control 
(Figure 13). Since this was not as effective as extract 1 at the same dose level, it was not 
investigated further. 
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Figure 11. Time-dependent MTT-assay of P. aurea crude fractions. HeLa cells were plated at a 
density of 2000 cells/well and treated at 0.5 mg/mL. Cell viability was determined against the day 7 
solvent control (MeOH). Error bars reflect SEM. 
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Figure 12. Time-dependent MTT-assay of P. aurea crude fractions. HeLa cells were plated at a 
density of 2000 cells/well and treated at 0.1 mg/mL. Cell viability was determined against the day 7 
solvent control (MeOH). Error bars reflect SEM. 
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Figure 13. Time-dependent MTT-assay of P. aurea crude fraction. HeLa cells were plated at a density 
of 1500 cells/well and treated at 0.5 mg/mL. Cell viability was determined against the day 7 solvent 
control (H2O). Error bars reflect SEM. 
 
Because of its potent growth-inhibitory activity, Extract 1 was further assessed in a 
dose-dependent manner against multiple cancer cell lines. SK-OV 3 (ovarian cancer), MCF-7 
(breast cancer), H441 (lung cancer), HCT 16 (colon cancer), HeLa (cervical cancer), and 
HepG2 (liver cancer) cells were all treated with Extract 1. It was effective against all tested 
lines in a dose-dependent manner, dropping the viability below 50% for all cell lines but 
H441 at a dose of 0.5 mg/mL. All cell lines were dropped to below 20% viability at 1.0 
mg/mL with Extract 1 (Figure 14).  
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Figure 14. Multiple cell line dose-dependent MTT-assay of P. aurea crude ethanol extract. Cells were 
plated at a density of 3000 cells/well. Treatment was applied at well concentrations of 0.01, 0.5, and 
1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against the solvent 
controls. Error bars reflect the SEM. 
 
2.3.3.4 Laetiporus sp. 
Dose-dependent MTT assay show that crude extracts from Laetiporus sp. have 
growth-inhibitory activity Extract 1 was observed to show the strongest inhibition, dropping 
cell viability from treatment concentrations as low as 0.01 mg/mL. Cell viability had dropped 
to under 6% at concentrations greater than 0.5 mg/mL. Extracts 2 and 3 showed similar 
activity, again dropping cell viability around 50% at doses of 1.0 mg/mL. Overall, extract 4 
was not observed to affect cell growth (Figure 15). 
As the top inhibitory extract, extract 1 proceeded into time-dependent assays. Initially 
the extract was treated at a dose of 0.5 mg/mL, which yielded significant deviation from the 
control within 24 hours. Cell viability had dropped to 4.28% of the day 7 control and 
remained at this low value for the duration of the assay. On day 7, cell viability was 
measured at 2.38% of the control (Figure 16). A lower dose run was performed using a 
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treatment concentration of 0.1 mg/mL. Again, extract 1 caused significant deviation from the 
control within 24 hours of treatment, dropping cell viability to as low as 38.7% in day 6 
readings, before rising back up to 52.0% viability in day 7 (Figure 17). In summary, Extract 1 
from Laetiporus sp. was found to be a potent growth-inhibitor. 
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Figure 15. Dose-dependent MTT-assay of Laetiporus sp. crude extracts. HeLa cells were plated at a 
density of 3000 cells/well. Treatments were applied at well concentrations of 0.01, 0.05, 0.1, 0.5, and 
1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against the solvent 
controls (E1: MeOH, E2: H2O, E3: H2O, E4: H2O). Error bars reflect SEM. 
54 
 
0 5 0 1 0 0 1 5 0
0
5 0
1 0 0
T i m e  ( H o u r s )
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
M e O H  ( 2 . 5 % )
E 1  ( 0 . 5  m g / m L )
 
Figure 16. Time-dependent MTT-assay of crude extracts isolated from Laetiporus sp.. HeLa cells 
were plated at a density of 2000 cells/well and treated with E1 at 0.5 mg/mL. Cell viability was 
determined against the day 7 solvent control (MeOH). Error bars reflect SEM. 
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Figure 17. Time-dependent MTT-assay of E1 from Laetiporus sp.. HeLa cells were plated at a density 
of 2000 cells/well and treated with E1 at 0.1 mg/mL. Cell viability was determined against the day 7 
solvent control (MeOH). Error bars reflect SEM. 
 
2.3.3.5 Letharia vulpina (L.) Hue 
Dose-dependent assay of L. vulpina crude extracts showed evidence of growth-
inhibitory activity. Extract 1 was observed to significantly decrease cell viability at 
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concentrations of 0.1 mg/mL and greater, dropping cell viability to as low as 5.60% of the 
control. The remaining three extracts all showed similar inhibition trends, dropping cell 
viability between 53.6-67.1% of the control in 1.0 mg/mL treatments (Figure18). While 
methanol was selected as the initial solvent for extract 1, spot testing had also shown that it 
was somewhat soluble in water as well. Another dose-dependent assay was performed to see 
if activity would be retained using water as the solvent. A similar trend was observed, with 
significant declines in cell viability being seen in concentrations of 0.5 mg/mL or higher, 
ultimately dropping to 12.3% viability in 1.0 mg/mL dosing. Interestingly, the extract was 
observed to stimulate cell growth at lower doses, peaking at 149% cell viability in the 0.1 
mg/mL treatment (Figure 19). This suggests that the bioactive compounds found in this 
extract are water soluble. Water was subsequently used as a solvent for the time-dependent 
assays. 
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Figure 18. Dose-dependent MTT-assay of crude extracts isolated from L. vulpina. HeLa cells were 
plated at a density of 3000 cells/well. Treatments were applied at well concentrations of 0.01, 0.05, 
0.1, 0.5, and 1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against 
the solvent controls (E1: MeOH, E2: H2O, E3: H2O, E4: H2O). Error bars reflect SEM. 
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Figure 19. Dose-dependent MTT-assay of crude extract E1 from L. vulpina. HeLa cells were plated at 
a density of 3000 cells/well. Treatments were applied at well concentrations of 0.01, 0.05, 0.1, 0.5, and 
1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against the solvent 
control. Error bars reflect SEM. 
 
Extract 1, showing the strongest growth-inhibitory activity, was selected to proceed 
into time-dependent assays. An initial treatment concentration of 0.5 mg/mL was used. Cell 
viability had significantly dropped below that of the control within 24 hours of treatment, 
dropping to final values of 3.42% on day 7 (Figure 20). A second assay, using a treatment 
concentration of 0.1 mg/mL, was performed. The lower dose treatment showed significant 
deviation from the control on days 2 through 5, having a higher growth rate than the control. 
This trend ended by day 6 (Figure 21). This evidence suggests that extract 1 may be 
stimulatory at lower doses, and inhibitory at higher doses. However, further experiments 
would need to be performed to confirm this unexpected finding. 
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Figure 20. Time-dependent MTT-assay of crude extract E1 from L. vulpina. HeLa cells were plated at 
a density of 2000 cells/well and treated with E1 at 0.5 mg/mL. Cell viability was determined against 
the day 7 solvent control (H2O). Error bars reflect SEM. 
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Figure 21. Time-dependent MTT-assay of E1 from L. vulpina. HeLa cells were plated at a density of 
2000 cells/well and treated with E1 at 0.5 mg/mL. Cell viability was determined against the day 7 
solvent control (H2O). Error bars reflect SEM. 
 
2.3.3.6 Vulpicida canadensis (Räs.) J.-E. Mattsson & M. J. Lai 
Dose-dependent MTT assay of the V. canadensis crude extracts show that this lichen 
contains growth-inhibitory activity. The strongest inhibition was seen with extract 1, 
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significantly deviating from the control at all treatment concentrations. A maximum 
inhibition was seen in treatment concentrations of 0.5 mg/mL, dropping cell viability to 
6.16%. Extracts 2 and 4 showed similar trending, coming out in the middle with cell 
viabilities of 70.2% and 54.9% at the highest treatment concentration. The hot water extract 
(extract 3) was not observed to significantly affect cell growth in any of the treatment 
concentrations used (Figure 22). 
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Figure 22. Dose-dependent MTT-assay of crude extracts isolated from V. canadensis. HeLa cells were 
plated at a density of 3000 cells/well. Treatments were applied at well concentrations of 0.01, 0.05, 
0.1, 0.5, and 1.0 mg/mL for 48 hours prior to MTT application. Cell viability was standardized against 
the solvent control. Error bars reflect SEM. 
 
Time-dependent assays were performed on extract 1 due to its strong inhibitory 
activity. An initial assay was performed with a treatment concentration of 0.5 mg/mL. The 
sample was observed to significantly affect cell growth within 24 hours of treatment. At day 
7, the cell viability was at 2.57% of the control (Figure 23). A lower concentration of 0.1 
mg/mL was used in a second time-dependent assay. Cell growth began to deviate from the 
control at the 24-hour mark and continued to do so throughout the duration of the assay. Day 
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7 viability was measured at 44.4% of the control, suggesting this extract has the ability to 
inhibit cells at lower doses (Figure 24). In summary, Extract 1 from V. canadensis was found 
to have potent growth-inhibitory activity. 
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Figure 23. Time-dependent MTT-assay of E1 from V. canadensis. HeLa cells were plated at a density 
of 2000 cells/well and treated with E1 at 0.5 mg/mL. Cell viability was determined against the day 7 
solvent control (MeOH). Error bars reflect SEM. 
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Figure 24. Time-dependent MTT-assay of E1 from V. canadensis. HeLa cells were plated at a density 
of 2000 cells/well and treated with E1 at 0.1 mg/mL. Cell viability was determined against the day 7 
solvent control (MeOH). Error bars reflect SEM. 
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2.3.4 Immuno-stimulatory activity 
ELISA was performed on the supernatants of treated Raw 264.7 cells to determine 
which extracts stimulated TNF-α production. Initially cells were treated for 3 and 6-hour 
periods to determine which timeframe allowed enough activity to be seen on ELISA plates. 
The 6-hour incubation time was subsequently adopted for all of the later experiments. LPS 
was used as a positive control, to ensure cells were active, and to give a reference point for 
active fractions. All extracts were initially treated at a dose of 1.0 mg/mL, however for some 
cytotoxic extracts the concentration used were dropped to 0.1 mg/mL to ensure results were 
not the product of cell lysis. All extracts were subjected to three assays to ensure results were 
not the product of cell variability. Significance was tested with a student’s T-Test (p=0.05). 
2.3.4.1 Hericium coralloides (Scop.: Fr) Pers. 
In the first ELISA experiment, H. coralloides crude extracts E2 and E3 showed 
modest stimulatory activity. At both the 3 and 6-hour time points, these extracts were found 
to significantly deviate from the water control. Extract 4 was only significant after 6 hours of 
treatment. This being said, the top stimulatory activity, seen in E3 (821.25 pg/mL), was only 
15.10% of the LPS positive control (Figure 25). Repeat assays found similar results, with 
extracts 2, 3, and 4 deviating from the control. E3 remained the top stimulator of TNF-α, 
stimulating at a rate of 21-25% of LPS respectively (Figures 26-27). 
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Figure 25. ELISA 1 results for crude extracts of H. coralloides. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. Extracts were applied at a well concentration of 1.0 mg/mL and the supernatant solution was 
collected after incubations of 3 and 6 hours. Error bars represent SEM. 
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Figure 26. ELISA 2 results for crude extracts of H. coralloides. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. Extracts were applied at a well concentration of 1.0 mg/mL and the supernatant solutions were 
collected after 6 hours of treatment. Error bars represent SEM. 
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Figure 27. ELISA 3 results for crude extracts of H. coralloides. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. Extracts were applied at a well concentration of 1.0 mg/mL and the supernatant solutions were 
collected after 6 hours of treatment. Error bars represent SEM. 
 
2.3.4.2 Hydnellum diabolus Banker 
Extracts 2, 3 and 4 from Hydnellum diabolus was observed to significantly stimulate 
TNF-α production. Results were significant in both the 3 and 6-hour treatment timeframes. 
The top stimulator was E2, stimulating TNF-α production at 33.31% of the LPS positive 
control (Figure 28). E1 (0% of LPS) and E3 (27.72% of LPS) were observed to have 
cytotoxic effects on cells. Due to this, these extracts were treated at 0.1 mg/mL in the next 
assay, to determine if cytokine readings were the product of cell lysis, or actual stimulation. 
A second ELISA was performed, and all extracts were observed to deviate significantly from 
the control. Cytotoxic E1 and E3 were both observed to stimulate TNF-α production at their 
lowered treatment concentrations, however, cell death was still observed in treatment wells. 
E1 now stimulated at 23.27% and E3 at 30.39% of LPS (Figure 29). This suggests that there 
may be competing compounds within the extracts. E2 (32.83% of LPS) was observed to have 
some adverse effects on cells during this assay, and it was subsequently dropped to a 
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treatment concentration of 0.1 mg/mL. This would also allow for comparison between the 
first 3 extracts. As seen in Figure 30, E3 is the most stimulatory extract at the lowered dose 
of 0.1 mg/mL, stimulating at 21.25% of LPS. E1 was second most stimulatory at 17.79% of 
LPS and E2 came third at 21.25% of LPS. E2 was observed to be the least cytotoxic to Raw 
cells in the lower dose assay. 
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Figure 28. ELISA 1 results for crude extracts of H. diabolus. Raw 264.7 cells were plated at a density 
of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. 
Extracts were applied at a well concentration of 1.0 mg/mL and the supernatant solution was collected 
after incubations of 3 and 6 hours. Error bars represent SEM. 
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Figure 29. ELISA 2 results for crude extracts of H. diabolus. Raw 264.7 cells were plated at a density 
of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1 
and E3 were treated at 0.1 mg/mL due to cytotoxic activity against the cells. E2 and E4 were treated at 
1.0 mg/mL. The supernatant solutions were collected after 6 hours of treatment. Error bars represent 
SEM. 
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Figure 30. ELISA 3 results for crude extracts of H. diabolus. Raw 264.7 cells were plated at a density 
of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1, 
E2, and E3 were treated at concentrations of 0.1 mg/mL due to cytotoxic activity against cells. E4 was 
treated at 1.0 mg/mL. The supernatant solutions were collected after 6 hours of treatment. Error bars 
represent SEM. 
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2.3.4.3 Phaeolepiota aurea (Matt. ex Fr.) Maire 
In the initial ELISA experiments, crude extracts 2, 3 and 4 of P. aurea were found to 
have significant stimulatory activity. Top production of TNF-α was seen in the 6-hour 
treatment with E3, causing stimulation at rates 76.17% of LPS. E2 was the second most 
stimulatory, showing 21.67% the stimulation of LPS. E4 only stimulated at 11.19% of LPS 
(Figure 31). E1 was observed to kill cells and was thus diluted to 0.1 mg/mL in subsequent 
assays. However, E1 still caused cell death in the lower dose treatments. The second and 
third ELISA tests confirmed E3 as the most potent stimulator (86-98% of LPS), with E2 
close behind (59-77% of LPS, Figures 32-33). Due to its highly potent immuno-stimulatory 
activity which is as strong as the positive control LPS, E3 was selected as the source for the 
purification and characterization of immuno-stimulatory compound(s) described in detail in 
Chapter 3. 
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Figure 31. ELISA 1 results for crude extracts of P. aurea. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1 was 
dissolved in MeOH and all remaining extracts were dissolved in water. Extracts were applied at a well 
concentration of 1.0 mg/mL and the supernatant solution was collected after incubations of 3 and 6 
hours. Error bars represent SEM. 
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Figure 32. ELISA 2 results for crude extracts of P. aurea. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1, 
dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity against cells. 
E2, E3, and E4, dissolved in water, were treated at a concentration of 1.0 mg/mL. The supernatant 
solutions were collected after 6 hours of treatment. Error bars represent SEM. 
 
D
M
E
M
L
P
S
H
2
O
M
e
O
H E
1
E
2
E
3
E
4
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
T
N
F
-
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
L
)
 
Figure 33. ELISA 3 results for crude extracts of P. aurea. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1, 
dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity against cells. 
E2, E3, and E4, dissolved in water, were treated at a concentration of 1.0 mg/mL. The supernatant 
solutions were collected after 6 hours of treatment. Error bars represent SEM. 
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2.3.4.4 Laetiporus sp. 
In the first ELISA experiment with Laetiporus sp. crude extracts, LPS failed to 
stimulate cells. This was attributed to a bad batch of LPS solution. However, trends were still 
seen in the extract data, with E2, E3 and E4 all deviating from their solvent controls. The 
most potent extract was E3, followed by E2, and then E4. Accurate comparisons could not be 
made due to the low value of LPS (Figure 34). E1 was observed to kill cells at the 1.0 mg/mL 
concentration and was dropped to 0.1 mg/mL for subsequent assays, however, this extract 
still caused cell death at the lower dosing. In the subsequent two experiments, all extracts 
were observed to significantly deviate from the control. The stimulation now seen in E1, 
while low, suggests that there are competing compounds within this extract. E3 remained the 
most potent stimulator, exceeding the stimulation seen in LPS (117-126% of LPS). E2 
remained a close second, also exceeding LPS (115-119% of LPS). E4 was also significant, 
stimulating at values 51-60% of LPS (Figures 35-56). Due to their consistently potent 
activity, E2 and E3 are strong candidates for future investigation into finding potential novel 
immuno-stimulatory compounds. 
68 
 
D
M
E
M
L
P
S
H
2
O
M
e
O
H E
1
E
2
E
3
E
4
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
T
N
F
-
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
L
)
3   H o u r
6   H o u r
 
Figure 34. ELISA 1 results for crude extracts of Laetiporus sp.. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. E1 was dissolved in MeOH and E2, E3, E4 were dissolved in water. Extracts were applied at a 
well concentration of 1.0 mg/mL and the supernatant solution was collected after incubations of 3 and 
6 hours. Error bars represent SEM. 
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Figure 35. ELISA 2 results for crude extracts of Laetiporus sp.. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. E1, dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity 
against the cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. 
The supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. 
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Figure 36. ELISA 3 results for crude extracts of Laetiporus sp.. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. E1, dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity 
against the cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. 
The supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. (* value 
based off one sample well due to equipment limitations, actual value expected to be larger) 
 
2.3.4.5 Letharia vulpina (L.) Hue 
The initial ELISA experiment with L. vulpina crude extracts showed stimulatory 
trends with extracts 3 and 4. Due to a bad batch of LPS solution, the positive control was not 
observed to strongly stimulate TNF-α production. Due to this, only observations were made 
indicating extract 3 stimulated stronger than extract 4 (Figure 37). E1 was cytotoxic at the 
treatment dose of 1.0 mg/mL and was dropped to 0.1 mg/mL for all further assays, however, 
cell death was still observed in treatment wells. The same data trends were seen in the 
subsequent two ELISA experiments, with E3 and E4 showing significant stimulation. E3 
remained the most potent stimulator, showing values at 35-41% of LPS. E4 stimulated at 8-
17% of LPS (Figures 38-39). 
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Figure 37. ELISA 1 results for crude extracts of L. vulpina. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1 was 
dissolved in MeOH while E2, E3, and E4 were dissolved in water. Extracts were applied at a well 
concentration of 1.0 mg/mL and the supernatant solution was collected after incubations of 3 and 6 
hours. Error bars represent SEM. 
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Figure 38. ELISA 2 results for crude extracts of L. vulpina. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1, 
dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity against the 
cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. The 
supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. 
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Figure 39. ELISA 3 results for crude extracts of L. vulpina. Raw 264.7 cells were plated at a density of 
100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive control. E1, 
dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity against the 
cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. The 
supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. 
 
2.3.4.6 Vulpicida canadensis (Räs.) J.-E. Mattsson & M. J. Lai 
The initial ELISA experiment of V. canadensis crude extracts found stimulatory 
activity in extracts 2, 3, and 4. E4 was the most potent, followed by E2 and E3. E1 was 
observed to be cytotoxic at treatment concentration 1.0 mg/mL and was therefore dropped to 
0.1 mg/mL in subsequent assays. Cell death was still observed in E1 treatments at the 
lowered dose. Due to the lack of strong stimulation in LPS, attributed to a bad batch of 
solution, comparison values were not made for the first ELISA. Experiments 2 and 3 were 
more successful, showing E2 to be the most stimulatory at 28-47% of LPS. This was 
followed by E4 at 18-27% stimulation, and E3 at 15-20% stimulation (Figures 41-42). 
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Figure 40. ELISA 1 results for crude extracts of V. canadensis. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. Extracts were applied at a well concentration of 1.0 mg/mL and the supernatant solution was 
collected after incubations of 3 and 6 hours. Error bars represent SEM. 
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Figure 41. ELISA 2 results for crude extracts of V. canadensis. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. E1, dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity 
against the cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. 
The supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. 
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Figure 42. ELISA 3 results for crude extracts of V. canadensis. Raw 264.7 cells were plated at a 
density of 100,000 cells/well. LPS was treated at a well concentration of 500 ng/mL as a positive 
control. E1, dissolved in MeOH, was treated at a concentration of 0.1 mg/mL due to cytotoxic activity 
against the cells. E2, E3, and E4 were dissolved in water and treated at a concentration of 1.0 mg/mL. 
The supernatant solutions were collected after 6 hours of treatment. Error bars represent SEM. 
 
2.4 Discussion 
The initial proceedings of this study have yielded many interesting results. 
Identification of mushroom samples has proven the effectiveness of the ITS region for 
mushroom identification, as well as its limitations. While fresh collections show an ease in 
identification, aged specimens can be a challenge in both morphological and DNA 
identification, being prone to varying features as well as contamination, as seen in sample #4. 
As samples are collected from the environment, contaminating spores and molds can be an 
issue when proceeding with DNA analysis, especially since they would also be the target of 
fungal specific primers. Once identified, the history of the species studied could be 
determined. 
Hericium coralloides has not been subject to intense study. Previously, studies have 
found its extracts to contain antioxidant activity93–95. Erinacin E, isolated from this species, 
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has proven to be a highly selective agonist of the kappa opioid receptor, and it was suggested 
it could show similar effects as morphine, without the side effects75. A novel laccase was 
isolated in 2012, which showed significant activity against HIV-1 reverse transcriptase, but 
did not affect cancer cells when tested for anti-proliferative effects96. Additionally, isolated 
corallocins A-C were found to induce nerve growth factor (NGF) in human astrocytes97. 
Corallocin B was also observed to show anti-proliferative effects against MCF-7 and KB-3-1 
cancer cell lines97. A relative of H. coralloides, H. erinaceus, is well-known in traditional 
Chinese medicine, and has been studied extensively in recent years. Commonly known as 
Lion’s Mane, H. erinaceus has been found to contain many bioactive polysaccharides, 
proteins, lectins, phenols and terpenoids98–100; hericenones and erinacines isolated from this 
fungus have been shown to stimulate NGF98,99. Multiple studies have attributed a vast array 
of biological activities to H. erinaceus, including antitumor, immunomodulatory, 
neuroprotective, neuroregenerative, anti-oxidant, anti-hyperglycemia, anti-fatigue, anti-
aging, hepatoprotective, and gastroprotective effects99,100. Due to these effects, it has been 
used in the treatment of cancers, hepatic disorders, Alzheimer’s and Parkinson’s disease, 
dementia, schizophrenia, to improve sleep, to reduce menopause symptoms, as well as many 
other applications98–100. Due to its phylogenetic relationship, one may expect to find similar 
compounds within H. coralloides.  
While Hydnellum diabolus has been studied for ecological purposes, very little 
research has been performed in regards to its potential bioactivities. The only study directly 
related to bioactivity in this species was the isolation of the anticoagulant atromentin from 
ethanolic extracts; its activity was comparable to that of heparin101. Additional p-terphenyl 
derivatives have been isolated from a variety of other Hydnellum species102–105. Of these, 
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identified bioactivity was found to be α-glucosidase inhibitors104. Moderate antioxidant 
activity has been seen in other species106, however, very few studies have looked at 
bioactivity of the isolated compounds. The limited bioactivity studies in this and related 
species makes it an obvious candidate for future research. 
Similarly, there has been relatively little study done on Phaeolepiota aurea. At once 
thought to be edible, tests have found this species to contain trace amounts of hydrogen 
cyanide107, and it is no longer recommended as a food source. Many studies pertain to the 
taxonomy and ecology of this species, but as of our study, only one has approached it in 
regards to isolation and identification of bioactive compounds. Two lectins have been 
isolated from fruiting bodies extracted in saline solution. These were found to be N-
acetylgalactosamine specific, and showed a preference for type A erythrocytes in 
agglutination assays108. As this species is the only one in its genus, it has no related species 
showing bioactivity. This species has high potential since its medical potential is 
uncharacterized. 
While the species identity of the Laetiporus specimen remains unknown, some 
members of this genus have been well studied. Of particular interest is L. sulphureus, a well-
known edible mushroom. Known as “chicken of the woods”, it is a highly prized food in 
many cultures. Traditionally, it has been used for treating pyretic diseases, coughs, gastric 
cancer and rheumatism109,110. Studies have found it to be a rich source of polysaccharides, 
proteins, polysaccharide-protein complexes, triterpenoids, organic acids, benzofurans, 
flavonoids, coumarins and nitrogen containing compounds109,111. These compounds have 
elicited an array of activities, including antioxidant, antimicrobial, anti-proliferative, food 
preserving, hepatoprotective, anti-inflammatory, immuno-stimulatory, and anti-diabetic109–
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112. Overall, L. sulphureus is well characterized for bioactivity, however novel compounds 
are still being identified from this species113. Alternatively, as the specimen was well aged 
and was noted to have mold contaminants in DNA analysis, one could expect that activity 
may arise from compounds contributed by such contaminants. Gibellulopsis nigrescens does 
not appear to be characterized for bioactivity, and as such, its isolation may lead to novel 
findings. Due to the condition of the specimen, an exact species identity is required before 
pursuing the Laetiporus specimen for further characterization. 
Letharia vulpina obtains its bright colour from vulpinic acid; known to be toxic, this 
lichen has been used as a poison in wolf bait80,114. Acetone extracts of this lichen have shown 
antibacterial effects, being effective against multiple strains of bacteria, including 
methicillin-resistant Staphylococcus aureus115,116. Extracts have also proven cytotoxic to 
Burkitt’s lymphoma (Raji) cells117. Vulpinic acid has in itself been proven to show anti-
proliferative effects against Hep-G2, NS20Y, and HUVEC cells. Interestingly, it was more 
cytotoxic to the cancer cells than normal cells, and showed a stronger anti-angiogenic activity 
in normal cells118. Vulpinic acid also shows photoprotective abilities119. While many studies 
have explored the ecology of this species, few involve its bioactive compounds, leaving this a 
species of interest for future investigation. 
Vulpicida canadensis also contains vulpinic acid, as well as usnic and pinastric 
acids120. Its extracts have shown antioxidant, and neuroprotective activities120. Cytotoxic 
activity was observed against Raji117, Hep-G2, and MCF-7 cells120. Acetone extracts also 
showed antibacterial properties against multiple bacterial strains116. This lichen has yet to be 
characterized for any further bioactivities. 
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In this chapter, the bioassay results show support for previously discovered activities, 
as well as some novel findings. MTT assay results show a strong trend for ethanol extracts 
being the most cytotoxic. H. diabolus, P. aurea, Laetiporus sp., L. vulpina, and V. canadensis 
all showed strong anti-proliferative activity within E1, suggesting all contain bioactive small 
molecules. Of these, only Laetiporus sp. and V. canadensis were observed to retain 
significant activity in the low dose time-dependent assays, suggesting the compounds in their 
ethanol extracts are more potent, or compose a larger percentage of the fraction respectively. 
However, cytotoxic activity has already been reported in these two species. Additionally, the 
growth inhibitory effects of L. vulpina have been reported in acetone extracts. The anti-
proliferative activity observed in P. aurea and H. diabolus appears to be novel findings, as 
they have not been previously studied for growth-inhibitory effects. 
The results from ELISA experiments showed that all mushrooms studied contain 
some immuno-stimulatory activity. This is not unexpected, as it is suggested that all 
mushrooms could contain immuno-stimulatory compounds, as they generally contain β-
glucans, which are components of the cell wall of fungal cells84. The stimulatory compounds 
are part of the structure of mushrooms, not just secondary compounds. As such, the strongest 
stimulation was often observed in E3, the hot water extract, suspected to contain water 
soluble polysaccharides.  The strong immuno-stimulatory effects seen in Laetiporus sp. 
support previous findings in this genus. The immuno-stimulatory effects observed in all other 
species studied appear to be novel at the time of this study. However, of these novel findings, 
P. aurea remains of the highest interest due to its stimulation at levels comparable to LPS.  
An unexpected finding was that some cytotoxic extracts were observed to stimulate 
growth in their lower dose treatments. L. vulpina’s ethanol extract was observed to have a 
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brief stimulatory spike in its dose-dependent MTT assay, initially thought to be due to cell 
variance. However, upon low dose time-dependent assay, cells were observed to grow at a 
rate greater than the control for a large portion of the assay. This may suggest there are 
competing compounds within the extracts and raises the concern that some bioactivity may 
be masked by other compounds. Alternatively, one may also suggest that the compound of 
interest is only toxic at higher doses, being relatively benign in small amounts. This can also 
be seen in the results from ELISA experiments, with the cytotoxic E1 extracts showing some 
stimulatory effects when diluted. 
Due to the production of salt when neutralizing the highly alkaline sodium hydroxide 
extracts (E4), the mass collected exceeded the starting mass of material extracted. As dialysis 
was not adopted at this time, a large portion of the mass used to make solutions would have 
been caused by this salt, and therefore less of the crude extract made it into treatment 
solutions. This could have caused an underestimation of the activity of the E4 extracts within 
the bioassays. These extracts could show stronger activity upon removal of the salt for 
accurate concentration applications in the assays. 
By pursuing extracts with stronger observed activity, one could assume that there is 
an active compound in larger quantity, and thus be easier to purify in larger amounts. 
Alternatively, there could be small amounts of a far more potent compound, in which case 
purification would require a larger scale approach to isolate enough compound for further 
analysis. Based on the strength of the above results, the novelty of findings, and due to 
availability of raw material, P. aurea E3 extract was selected for further studies in an attempt 
to purify, characterize and potentially identify the compound responsible for immuno-
stimulatory activity. The anti-proliferative activity of E1 extract of P. aurea was not pursued 
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because it could contain hydrogen cyanide107 which potentially could have given rise to the 
cytotoxic activity.  
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Chapter 3: Purification and Characterization of an Immuno-Stimulatory Compound 
from Phaeolepiota aurea 
3.1 Introduction 
Based on the literature search of the mushroom species as well as the results of the 
biological evaluation of their crude extracts, in the previous chapter, I decided to further 
investigate the immuno-stimulatory activity of the species Phaeolepiota aurea. Prior to our 
study, the immuno-stimulatory activity of P. aurea has never been described. Herein, I 
provide the purification scheme for the isolation of a large molecular weight compound with 
immuno-stimulatory activity from P. aurea. I also provide an initial characterization of the 
immuno-stimulatory compound. 
3.2 Methods 
3.2.1 Collection, Identification, and Re-extraction of Phaeolepiota aurea 
Prior to purification attempts, a fresh batch of P. aurea E3 extract was prepared. A 
second batch of P. aurea fruiting bodies was collected from the same location on the UNBC 
campus trails in October 2014. The samples were morphologically and DNA identified as 
outlined in Chapter #2. Fruiting bodies were dried in an oven and ground to a powder with a 
flour like consistency. The powdered mushroom was extracted using the manual extraction 
method outlined in Figure 1. 
One hundred grams of powdered mushroom was mixed with 1600 mL of 80% EtOH. 
The mixture was heated to 65℃ for 3 hours then left to cool overnight. The solution was then 
suction filtered through a no. 2 filter paper. The filtrate was rotary-evaporated and slant 
frozen at -80℃ before being lyophilized.  
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The residue from ethanol extraction was then transferred to a clean flask and topped 
up with 1600 mL of 50% MeOH. This was heated to 65℃ for 3 hours and allowed to cool 
overnight. This was then filtered through a no.2 filter and required no neutralization prior to 
rotary-evaporating, slant freezing at -80℃, and lyophilizing.  
The residue from methanol extraction was transferred to a clean flask and topped up 
with 1600 mL of distilled water. The mixture was then heated to 65℃ for 6 hours and 
allowed to cool overnight. The solution was suction-filtered through no.2 filter papers, 
changing the filter three times due to clogging. The filtrate was then neutralized from pH 
5.44 to pH 7.00 with the addition of 5% NaOH. This was then rotary-evaporated, slant frozen 
at -80℃, and lyophilized. The second batch of extract yielded 4.5183 g of P. aurea E3 
(4.51% yield) and was used in polysaccharide targeted purification when the first batch of 
hot water extract was depleted. 
3.2.2 Column Chromatography 
Purification was performed on the crude hot water extracts E3 collected from the 
fruiting bodies of P. aurea. Activity of semi-purified samples was assessed using ELISA 
during all purification steps to ensure that the activity had not been lost. Initially, size-
exclusion chromatography (Sephadex LH-20) was used to separate the crude extract into 
fractions. Active fractions were then tested for carbohydrate and protein content. Following 
this, a new approach to purification was attempted based on the belief that the active 
compound contained polysaccharides. Precipitation methods (see pages 87-88) were then 
applied to the crude hot water extract to remove contaminants from the sample. Following 
this, the precipitated material was subjected to ion-exchange chromatography (DEAE 
Sephadex A-50). The eluted material was then run on a high-resolution chromatography 
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column (Sephacryl S500 HR). Active fractions were then subjected to carbohydrate and 
protein quantification, as well as enzyme digestion studies to determine whether the active 
components of the compound were protein and/or carbohydrate. Active fractions were finally 
pooled and lyophilized for further characterization studies. 
3.2.2.1 Size-Exclusion Chromatography 
Sephadex LH-20 was used as a preliminary separation agent in an attempt to estimate 
the size of active compounds. With an exclusion limit of 4-5 kDa, it is commonly used for 
the purification of natural products targeting low molecular weight compounds121. A small-
scale size exclusion column was prepared for preliminary analysis. Sephadex LH-20 was 
prepared as per the manufacturer’s protocol121. Media was swelled in an excess of sterile 
water, overnight, at room temperature. A 75% packed media and 25% water slurry was made 
by drawing off the excess supernatant water and swirling the settled media into suspension. 
This slurry was poured into a modified serological pipette and packed with water via gravity 
drip. After running over 3 bed volumes of water through the column, its final packed volume 
was 30.4 mL. 
Phaeolepiota aurea E3 crude extract was prepared at a concentration of 100 mg/mL 
in sterile water. This solution was pH neutralized and filter sterilized through a 0.2 µm 
syringe filter. Six-hundred microliters (2% of bed volume) of the sterile solution was loaded 
onto the column. The sample was run with sterile water via gravity drip (approximately 21.76 
mL/hour). A total of forty 1.5 mL fractions were collected by running 2 bed volumes of 
water through the column. The column was flushed with a minimum of two bed volumes (60 
mL) of water prior to running the next batch of sample. A total of 3 runs were performed 
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using the small-scale column. All collected fractions were stored at 4℃ until ELISA and 
MTT assays were performed (as per protocols on pages 17-22). 
A large-scale column was prepared in a similar fashion. Sephadex LH-20 media was 
swelled in an excess of sterile water. The swelled media and additional sterile water was 
degassed to prep for column packing. A 75% slurry was made with the degassed media and 
poured into a C16/70 column. The column was then packed at a flow rate of 2.5 mL/min, 
resulting in a final bed volume of approximately 128.68 mL. A 100 mg/mL solution of P. 
aurea crude extract E3 dissolved in water was prepared as above, and 2.2 mL was loaded 
onto the column. The column was run at a flow rate of 1.0 mL/min with degassed sterile 
water. Fractions were collected every 10 minutes with the use of an auto-collector, for a total 
of 26 fractions (approximately 2 bed volumes). The column was flushed with a minimum of 
2 bed volumes prior to running more sample. The large-scale column was run a second time 
under the same experimental conditions. Collected fractions were stored at 4℃ for further 
analysis. 
3.2.2.2 Ion-Exchange Chromatography 
DEAE Sephadex A50 is a weak anion exchange media for use in ion-exchange 
chromatography. Under the correctly buffered conditions, negatively charged compounds 
will bind to the media, allowing positively charged compounds to flow through. The bound 
compounds could then be removed from the column by flushing it with a buffer containing 
NaCl. The chloride ions displace the bound ions from the media, allowing them to be eluted. 
This allows for the separation of compounds by their net charge. As DEAE Sephadex A50 is 
less ridged in structure and is prone to variability in volume relative to pH and ionic strength, 
it has been suggested that this media is better suited to a batch method approach for 
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separation122. Batch method involves equilibrating the media in a buffer of choice, and then 
stirring it in with the solution to be treated. Once the slurry reaches equilibrium, it can be 
filtered and washed with more buffer. The filtrate can then be applied to a new media bed to 
capture any additional compounds. The filtered media would then be stirred in with elution 
buffer to release the bound compounds and filtered to retrieve the product122. 
  Initially a small scale approach was used to test various buffer systems for their 
ability to allow the active compound to bind to the media.123. This was done by equilibrating 
DEAE Sephadex A50 in one of 6 buffer systems: N-methylpiperazine, piperazine, bis-TRIS, 
triethanolamine, 1,3-diaminopropane, and water. Buffer was changed a minimum of 3 times 
during the swelling of the media. Equilibrated media was then mixed with an equal volume 
of 1 mg/mL post-Sevag extract (see precipitation methods, page 84-85) dissolved in loading 
buffer. This was left for two hours to bind. Treatments were then spun down at 200 x g and 
the supernatant solution drawn off as the flow through. The media beds were then washed 
with an equal volume of loading buffer, and again spun down and the supernatant drawn off 
as the wash. Media beds were then treated with elution buffer (1 M NaCl in loading buffer) 
for 30 minutes before being spun down and the supernatant collected as the elution. Solutions 
were stored at 4℃. The collected samples were pH neutralized prior to performing ELISA. 
A two-stage batch method approach was taken when experiments were scaled up. 
Treatment was initially applied to a primary media bed and the filtrate from this was then 
applied to a secondary media bed to bind any compound that may have been in excess. 
DEAE Sephadex A50 media was swelled in a 0.2 M NaCl overnight, to prevent the beads 
from swelling too quickly and breaking122. This solution was drawn off the following day 
and the media was topped up with an excess of pure milli-Q water. The water was changed 
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on the swelling media an additional 3 times during swelling. The swelled media was then 
suction filtered with a bottle top filter (Filtropur BT50 0.2, 500 mL) and divided between two 
flasks. One media bed was topped up with excess milli-Q water and set aside. The other was 
topped up to the top of media bed with milli-Q water, and a solution of post-Sevag sample 
was applied. This was swirled into the media and left to bind for 2 hours. The media was then 
filtered and rinsed with fresh milli-Q water. Once filtered, the media was transferred into a 
flask and topped up with an excess of 1-2 M NaCl solution. This was left for 1 hour before 
the media bed was filtered and rinsed with additional NaCl solution. The media bed was 
transferred to a flask and topped up with excess milli-Q water to begin re-swelling. The 
elution was set aside. 
The water was filtered off the secondary media bed, and the filtrate from the primary 
media bed was applied to it. This was left to bind excess compound for an hour before the 
secondary media bed was filtered and transferred to a flask. It was then topped up with 1-2 M 
NaCl solution for 30 minutes. The media bed was then filtered and rinsed with excess NaCl 
solution. The filtered media was transferred to a flask and topped up with excess milli-Q 
water to begin re-swelling the media. The elution was combined with the elution from the 
primary media bed. 
The combined elutions were rotary-evaporated to reduce their volume. The 
concentrated elution was then subject to dialysis to remove the NaCl. Concentrated solution 
was poured into 3500 MWCO Snakeskin Dialysis Tubing and tied off. The dialysis tubes 
were suspended in an excess of milli-Q water with stirring. This was stored at 4℃ for the 
duration of dialysis. Water was changed a minimum of 5 times depending on salt 
concentrations of tubes (dependent on scale of experiment). Dialyzed samples were then 
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rotary-evaporated to workable volumes, slant frozen and lyophilized. Dried sample was then 
subject to ELISA and further purification. 
3.2.2.3 High-Resolution Size-Exclusion Chromatography using Sephacryl S-500 
This portion of the purification was performed with the help of Mr. Sebastian 
Mackedenski. A HiPrep 26/60 Sephacryl S-500 HR column was obtained from GE 
Healthcare. This column has a fractionation range of 4 x 104 – 2 x 107 Da and is intended for 
the separation of polysaccharides and macromolecules. The column was loaded onto an 
AKTA PURE chromatography system. The column was equilibrated with degassed sterile 
water. Dextran standards were run to determine the size separation of the column. The 
column was flushed with more water prior to performing a sample run. One hundred 
milligrams of post DEAE sample was dissolved in 2.0 mL of sterile water. The solution was 
centrifuged at 10,000 x g for 10 minutes to pellet out any insoluble material. The supernatant 
solution was drawn off and loaded into a 2 mL injection loop on the AKTA PURE system. 
This was then loaded onto the column by the system. The column was run at a flow rate of 
1.3 mL/min, collecting a total of fifty 10 mL fractions with the use of a fraction collector. 
Following the water run, the column was flushed with a 150 mM NaCl solution. This was run 
at a flow rate of 1.3 mL/min, collecting an additional fifty 10 mL fractions. Collected 
fractions were stored in a 4℃ cooler until used in further assays. The column was re-
equilibrated with sterile water prior to running more sample. A total of 4 runs were 
performed on the high-resolution column. The three most active fractions of each run were 
pooled, lyophilized and sent for structural characterization. The most active fractions seen in 
ELISA were sent for cytokine analysis using Mouse Cytokine Array/Chemokine Array 32-
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Plex (Eve Technologies Corporation, Calgary) after treatment on mouse macrophage Raw 
264.7 cells. 
3.2.3 Carbohydrate Quantification 
Initially, a total carbohydrate colorimetric assay kit (BioVision, USA) was used to 
determine the carbohydrate content of post-column fractions. The assay was performed based 
on the manufacturer’s protocol. Glucose standards were prepared via dilution in distilled 
water in their respective wells on a 96-well plate (0, 4, 8, 12, 16, 20 µg/well), for a total of 30 
µL/well. Samples were then loaded in duplicate onto the plate at a volume of 30 µL/well. 
Concentrated sulfuric acid (H2SO4) was added, 150 µL, to each of the standard and sample 
wells. The plate was shaken for one minute on a plate shaker, and then incubated at 90℃ for 
15 minutes. Following incubation, 30 µL of developer was added to each well and the plate 
was shaken for 5 minutes at room temperature. The absorbance was then read at 490 nm on a 
Synergy plate reader. A standard curve was plotted and the carbohydrate concentration of 
samples was calculated. 
Later in the study, a phenol-sulfuric carbohydrate assay was adopted for carbohydrate 
analysis. Glucose standards were prepared in distilled water (0-1000 µg/mL). Fifty 
microliters of standard or sample was loaded onto a 96-well plate in triplicate. To this, 50 µL 
of a 6% phenol solution was added, followed by an additional 125 µL of concentrated 
H2SO4. The plate was then incubated at room temperature for 30 minutes before the 
absorbance was read at 490 nm using a plate reader. A standard curve was plotted and the 
concentration of carbohydrate in each of the samples was calculated.  
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3.2.4 Protein Quantification 
A Pierce BCA Protein Assay Kit (Thermo Scientific, USA) was used to determine the 
protein content of post-column fractions. The assay was performed as according to the 
manufacturer protocol124. BSA standards were prepared by dilution in water (0-2000 µg/mL). 
The BCA working reagent was made by mixing 50 parts of BCA Reagent A with 1 part of 
BCA Reagent B. Twenty-five microliters of either standard or sample was pipetted into the 
wells of a 96 well plate, in duplicate. To this, 200 µL of BCA working reagent was added. 
The plate was shaken for 30 seconds on a plate shaker and then covered and incubated at 
37℃ for 30 minutes. Following incubation, the plate was allowed to cool to room 
temperature before the absorbance was read at 562 nm using a plate reader. A standard curve 
was plotted and the protein content of the samples was calculated. 
3.2.5 Precipitation Methods 
When dealing with hot water extracts, a common starting point for purification is the 
use of precipitation to help remove impurities from the sample, often used in the isolation of 
polysaccharides84. Two methods of precipitation were initially compared; ethanol 
precipitation and the Sevag method125. 
For the ethanol precipitation, a 40 mg/mL solution of crude E3 was prepared. This 
was mixed with 5 volumes (or greater) of 100% EtOH and placed in a -20℃ freezer for an 
hour to facilitate precipitation. The precipitate solution was then centrifuged at 3000 RPM for 
10 minutes to form a pellet. The supernatant solution was drawn off and the pellet was 
washed with chilled 100% EtOH. The EtOH was drawn off and the pellet was resuspended in 
a small amount of sterile water before being slant frozen at -80℃ and lyophilized. 
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Sevag method involved shaking the sample with a chloroform solution. Crude E3 was 
dissolved in water to make a 40 mg/mL solution. A 1/5 butanol-chloroform solution was also 
prepared. Equal parts of E3 and butanol chloroform solution were mixed and shaken 
vigorously for 5-10 minutes. The samples were then centrifuged at 3000 RPM for 10 minutes 
to separate the organic and aqueous layers. The aqueous supernatant solution was drawn off, 
being careful not to disturb the interphase, and transferred to a new tube. This was topped up 
with an equal part of fresh butanol-chloroform solution and shaken again for 5 – 10 minutes 
before being centrifuged and the supernatant collected. This was repeated for a total of 3 
chloroform shakes (or until little to no denatured protein was observed in the interphase). 
After the final shake, the supernatant solution was drawn off and subject to ethanol 
precipitation as per the preceding procedure. Dried precipitates were then subject to ELISA 
and further purification. 
3.2.6 Enzyme Digestion 
In order to determine the active component of the immuno-stimulatory compound of 
P. aurea, an enzyme digestion was performed on the bioactive fractions collected from 
Sephacryl-S500 run. It was expected that the activity would be reduced or eliminated if the 
active component was digested. Three enzymes were used for this purpose: cellulase, 
amyloglucosidase, and proteinase-K (Sigma Aldrich). Cellulase and amyloglucosidase target 
polysaccharides, with cellulase hydrolyzing endo-1,4-β-D-glucosidic linkages and 
amyloglucosidase hydrolyzing α-D-glucosidic bonds. Proteinase-K is a non-specific protein 
digester, often used to remove protein contaminants from DNA samples. This enzyme is 
known to cleave peptide bonds adjacent to carboxyl groups. 
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Post-Sephacryl 500 fraction, 2 mg/mL Krestin (PSK), and sterile water samples were 
aliquoted into clean Eppendorf tubes, 250 µL each. A 109 mg/mL cellulase solution was 
prepared by dissolving 50 mg cellulase in 458 µL of sterile water (120 units/mL). A 5 
mg/mL solution of amyloglucosidase was prepared by dissolving the contents of a 5 mg vial 
in 1.0 mL of sterile water (approximately 225 units/mL). Proteinase-K was available in 
solution (600 units/mL). Cellulase was treated into samples at two dose levels; 1 unit and 3 
units. This was done by adding 8.33 µL or 25 µL of the prepared solution. Amyloglucosidase 
was treated into samples at doses of 0.3 unit and 1 unit, by adding 6.6 µL or 22.2 µL of the 
prepared enzyme solution. Proteinase-K was treated at a ratio of 1:50 and 1:10, as suggested 
by Mr. Sebastian Mackedenski. Five microliters or 25 µL of the enzyme solution was added 
into sample vials, equaling doses of 3 or 15 units. Twenty-five microliters of sterile water 
was added to the controls to mimic the dilution effect of treatments. All treatments were then 
placed in a heating block and heated to 37℃ for 2 hours. Following this, the samples were 
brought up to 80℃ for 30 minutes, to denature the enzymes. Samples were then stored at 4℃ 
until ELISA was performed. 
A higher dose repeat of cellulase and amyloglucosidase digestion was performed 
using the same procedure. In this experiment, both enzymes were treated at doses of 10 and 
30 units. Post digestion samples were stored at 4℃ until ELISA was performed. 
3.3 Results 
3.3.1 Sephadex LH-20 
Based on the bed volume of the small scale Sephadex LH-20 column, and an assumed 
35% exclusion volume (based on previous researcher’s findings), the exclusion volume 
would consist of fractions LH1-7. A front of activity was observed at this limit, with both 
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immuno-stimulatory and cytotoxic activity seen in the early stages of column elution. As 
shown in Figure 43, the stimulatory activity was observed at the front of elution and seen to 
taper off slowly over the column run, with maximum stimulation being observed in fractions 
LH7 and LH9-11. Cytotoxic activity was prominent at the exclusion limit, with fraction LH8 
killing Raw cells in the first run, and fractions LH7-8 killing cells in the second run (Figure 
44). These trends were reproduceable amongst column runs, however minor shifts in the 
fractions were observed due to loading error, as the column was manually loaded and ran 
(Figure 44). MTT assay was performed, encompassing the cytotoxic fractions of column runs 
1-3. As seen in Figure 45 (representative data), fractions LH7-9 were cytotoxic against HeLa 
cells. Based on these observations, it was suspected that the bioactive compound(s) of 
interest is relatively large in size. 
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Figure 43. ELISA of post-Sephadex LH20 fractions from the first small column run. Raw 264.7 cells 
were plated at a density of 100,000 cells/well. Fractions were treated at a 50% dilution in wells. LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Fraction 8 was 
observed to kill cells. Error bars represent SEM. 
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Figure 44. ELISA of post-Sephadex LH20 fractions, comparing small column runs 1 and 2. Raw 
264.7 cells were plated at a density of 100,000 cells/well. Fractions were treated at a 50% dilution in 
wells. LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). 
Fraction 7 was observed to kill cells in run #2, and fraction 8 was observed to be cytotoxic in both 
runs. Error bars represent SEM. 
 
L
H
3
L
H
4
L
H
5
L
H
6
L
H
7
L
H
8
L
H
9
L
H
1
0
L
H
1
1
L
H
1
2
L
H
1
3
L
H
1
4
L
H
1
5
L
H
1
6
L
H
1
7
L
H
1
8
L
H
1
9
L
H
2
0
0
5 0
1 0 0
1 5 0
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
 
Figure 45. MTT assay of post-Sephadex LH-20 small column run #3. HeLa cells were plated at a 
density of 3000 cells/well. Fractions were 50% diluted in the treatment wells. Plates were scanned after 
48 hours of treatment. Error bars represent SEM. 
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A scaled-up column was used in an attempt to achieve better separation of the 
compounds. It was calculated to have its exclusion volume occurring within fractions LH1-5. 
Once again, cytotoxic activity was observed to elute close to this exclusion value. Again, a 
spread in cytotoxic activity was observed with run #2, which was believed to be caused by a 
headspace formed during loading of the column. Interestingly, it appears that there may be 
two compounds causing cytotoxic activity, with drops in cell viability being seen around 
fraction LH5 and then again at fraction LH8 (Figure 46). ELISA found a stimulatory spike 
between fractions LH7-10 for the first large column run, which shifted to LH8-10 for the 
second column run. Peak stimulation was observed in fraction LH8 of both runs (Figure 47). 
The shift was again believed to be due to loading error or may show that flushing the column 
with water alone may not be removing all residues from the media.  
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Figure 46. MTT assay of post-Sephadex LH-20 large column runs 1 and 2. HeLa cells were plated at a 
density of 3000 cells/well. Fractions were 50% diluted in the treatment wells. Plates were scanned after 
48 hours of treatment. Error bars represent SEM. 
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Figure 47. ELISA of post-Sephadex LH20 fractions, comparing large column runs 1 and 2. Raw 264.7 
cells were plated at a density of 100,000 cells/well. Fractions were treated at a 50% dilution in wells. 
LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Fractions 
LH5 and LH6 were observed to kill cells in both runs. Error bars represent SEM. 
 
3.3.2 Carbohydrate and Protein Quantification 
Large column Sephadex LH-20 fractions were subject to carbohydrate and protein 
quantification of the active fractions. Fractions LH5-10 were tested in an attempt to 
determine the makeup of the fractions, and thus, what compounds may be responsible for 
activity. The strongest stimulatory activity was seen in fraction LH8 (Figure 47), which 
corresponded to the highest carbohydrate content seen in the active fractions (Figure 48), as 
well as the second strongest peak in protein content (Figure 49). Likewise, the strongest 
cytotoxic activity was observed in fraction LH5 (Figure 46), which was observed to have the 
highest protein concentration of the tested fractions (Figure 49). In order to determine the 
effects of protein content on immuno-stimulatory activity, active fractions were heated to 
95℃ for 40 minutes in an attempt to denature protein within the samples. Heat treatment was 
only observed to significantly affect fraction LH8 of the first column run, causing a mild 
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drop in TNF-α production relative to the untreated fraction, but not completely eliminating 
activity (Figure 50). Due to this, it was believed that the fractions still contained a mixture of 
bioactive compounds. As the activity was not completely removed with heat, and due to the 
high carbohydrate content, it was suspected that the stimulatory activity seen in fraction LH8 
was partially caused by carbohydrates. The fact that heat treatment was not observed to affect 
fraction LH7 or LH9 also suggests the bioactive compound is not entirely made up of 
protein. It was decided that a more targeted approach would be taken to purify the bioactive 
compound(s) from the crude P. aurea extract. 
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Figure 48. Total Carbohydrate Assay Kit results for large column Sephadex LH-20 runs 1 and 2. 
Fraction 8 of both runs exceeded the bounds of the Synergy 2 plate reader and would be greater than 
3200 µg/mL in concentration based on the maximum absorbance of the machine. Error bars represent 
SEM. 
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Figure 49. Pierce BCA Protein Assay Kit results for Sephadex LH-20 large column runs 1 and 2. Error 
bars represent SEM. 
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Figure 50. Effects of heat on immuno-stimulatory activities seen in post-Sephadex LH-20 fractions. 
Active fractions were heated to 95℃ for 40 minutes. Error bars represent SEM. 
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3.3.3 Precipitation Methods 
A Sevag purification method was optimized and compared against simple ethanol 
precipitation. Sevag purification was observed to effectively remove contaminants, showing 
little to no interphase material after 3-4 chloroform shakes with equal volumes of 40 mg/mL 
crude extract E3. Sevag method produced yields between 37%-52% of starting material 
while ethanol precipitation alone yielded approximately 50% of starting material. The yield 
was seen to improve slightly with the use of a larger EtOH volume ratio during the 
precipitation steps. Post-Sevag precipitates were observed to show significant deviation from 
the crude E3 activity, having a slightly higher stimulatory value than its crude predecessor 
(Figure 51). Ethanol precipitation alone did not significantly improve the activity of crude 
E3. A dose-dependent assay also confirmed that Sevag precipitation was more effective than 
ethanol precipitation alone, showing significantly higher activity at all tested concentrations, 
whereas ethanol precipitates were only significantly higher at doses of 0.05 and 0.5 mg/mL 
(Figure 52). Due to its higher stimulatory values which suggests its effectiveness as a 
purification step, the Sevag method was adopted as the first step in the purification of the 
immuno-stimulatory compound(s) from crude extract E3 of P. aurea. 
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Figure 51. ELISA of precipitates from E3 purification: comparing Sevag method with ethanol 
precipitation. Raw 264.7 cells were plated at a density of 100,000 cells/well. Treatments were applied 
at well concentrations of 1.0 mg/mL. LPS was treated at a well concentration of 500 ng/mL as a 
positive control (data not shown). Error bars represent SEM. 
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Figure 52. Concentration-dependent ELISA of precipitates from E3 purification: comparing Sevag 
method with ethanol precipitation. Raw 264.7 cells were plated at a density of 100,000 cells/well. 
Treatments were applied at well concentrations of 0.05, 0.1, 0.5, and 1.0 mg/mL. LPS was treated at a 
well concentration of 500 ng/mL as a positive control (data not shown). Error bars represent SEM. 
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3.3.4 DEAE Sephadex A50 
Small scale DEAE Sephadex ion-exchange chromatography was effectively used to 
choose a buffer system for the binding of bioactive compounds from Sevag-purified E3. The 
flow through collections were tested against the initial treatment solutions to see if there was 
a decrease in activity, suggesting that the active compounds had bound to the media. Samples 
were tested at a 1/8 dilution in wells to reduce buffer related toxicity and morphological 
effects seen in higher dose treatments. As shown in Figure 53, bis-TRIS was the only buffer 
that did not show significant deviation from the treatment solution in its flow through 
collection. All other buffers used showed some binding to different extents. The most 
effective system for binding of active compound was water, showing 82% decreased activity 
between treatment and flow through collections, suggesting that the bioactive compound(s) 
bound to the media when water was used. The second most effective buffer was 1,3-
diaminopropane, decreasing activity by 56% in its flow through collection (Figure 53). Due 
to its higher binding capacity, lack of toxicity, and ease of use, the water system was selected 
for large scale DEAE Sephadex A50 purification. Sodium chloride elution collected from the 
column was dialyzed to remove the salt before the sample was added to cells. Comparison of 
the water collections show that this system was effective in binding immuno-stimulatory 
compound, with the elution collection showing significantly higher activity than the flow 
through. However, the activity from the elution was statistically similar to that of the 
treatment solution (Figure 54).  
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Figure 53. ELISA of post-DEAE Sephadex A50 collections, comparing the effectiveness of different 
buffer systems. Controls are 20 mM buffer solution. Treatment solutions consisted of 1.0 mg/mL of 
post-Sevag precipitate dissolved in buffer. Raw 264.7 cells were plated at a density of 100,000 
cells/well. Solutions were applied to cells at a 1/8 dilution in wells (approximately 0.125 mg/mL). LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 54. ELISA of post-DEAE Sephadex A50 using water as a buffer system. Treatment solution 
consisted of 1.0 mg/mL of post-Sevag precipitate dissolved in water. Flow through and wash solutions 
were treated directly from their collections. Elution was dialyzed, lyophilized, and re-dissolved in 
water equal to the volume of solution originally applied to the media bed. Raw 264.7 cells were plated 
at a density of 100,000 cells/well. Solutions were applied to cells at a 1/8 dilution in wells 
(approximately 0.125 mg/mL). LPS was treated at a well concentration of 500 ng/mL as a positive 
control (data not shown). Error bars represent SEM. 
 
Large scale DEAE Sephadex A50 proceeded with similar results. The dialyzed 
elutions from large batch applications yields between 25-36% of the starting material. 
Interestingly, treating larger bed volumes with smaller amounts of post-Sevag precipitate 
caused smaller percent yields. As colour was still seen on the media following elution, it is 
suspected that a portion of the compound was not removed with 1 M NaCl elution. Elution 
buffer concentration was therefore increased to 2 M NaCl. However, this did not 
significantly improve yields in larger batch applications, and some colour still remained in 
the media. Eluted compound did not show any significant difference in activity from the 
post-Sevag precipitate (Figure 55). 
102 
 
H
2
O
S
e
v
a
g
 P
P
T
P
o
s
t  
D
E
A
E
0
2 0 0 0
4 0 0 0
6 0 0 0
T
N
F
-
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
L
)
 
Figure 55. ELISA of post-DEAE Sephadex A50 using water as a buffer system. Raw 264.7 cells were 
plated at a density of 100,000 cells/well. Solutions were applied to cells at a treatment concentration of 
0.5 mg/mL. LPS was treated at a well concentration of 500 ng/mL as a positive control (data not 
shown). Error bars represent SEM. 
 
3.3.5 Sephacryl S500 HR 
Elutions from the DEAE Sephadex A50 column were dialyzed and freeze dried. The 
powder was then used for high resolution size exclusion chromatography. In the first column 
run, a single significant peak of activity occurred within the fractions comprising 263-323 
mL elution volume. Of these the top three active fractions occurred between the elution 
volumes of 273-293 mL, corresponding to a compound sizing between 270 and 410 kDa 
(Figure 56). Carbohydrate and protein quantification of the active fractions found that the 
peak concentrations of these compounds corresponded with the peak of TNF-α production. It 
was noted that the shape of the active peak corresponded well with the shape of the protein 
peak, suggesting that protein may be a key component in activity (Figure 57). However, due 
to the strong presence of carbohydrate within the fractions, it was suspected that the active 
compound may be a carbohydrate-protein complex. The most active fraction, collected at 
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elution volume 283 mL, was subsequently used in enzyme digestion analysis in order to 
determine which component may be responsible for activity. Upon washing the column with 
0.15 M NaCl solution, a second peak was detected by the UV detector of the AKTA PURE 
system. It was decided that the NaCl wash would be collected following the second column 
run to test this peak for activity. 
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Figure 56. ELISA of fractions collected from Sephacryl S500 HR column chromatography. Post-
DEAE Sephadex A50 purified samples were loaded onto Sephacryl S-500 column. Fractions collected 
were applied to Raw cells in 96-well plates at a 50% dilution. LPS was treated at a well concentration 
of 500 ng/mL as a positive control (data not shown). Error bars represent SEM. In separate Sephacryl 
S500 runs, Dextran Standards were loaded and the fractions collected were analyzed for presence of 
the standards. 
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Figure 57. TNF-α production of the first Sephacryl S500 HR column run in relation to carbohydrate 
and protein content. Raw 264.7 cells were plated at a density of 100,000 cells/well. Eluted fractions 
were applied to wells at a 50% dilution. LPS was treated at a well concentration of 500 ng/mL as a 
positive control (data not shown). Error bars represent SEM. 
 
A second run of the Sephacryl S500 HR column was performed under similar 
conditions to the first run. Following a 483 mL elution of the column with water, the elution 
buffer was then switched to 0.15 M NaCl solution, collecting wash fractions to determine if 
active compounds had bound to the column. Again, a single significant active peak was 
observed within the water elution fractions, occurring between 283-333 mL elution. The top 
three active fractions occurred between 283-303 mL. The NaCl wash fractions yielded a 
single active peak as well, occurring between elution volumes of 776-796 mL (Figure 58), 
suggesting that some active compound may be binding to the column under water elution 
conditions. Carbohydrate and protein analysis of the active fractions found the presence of 
both compounds within the active fractions, again with the general shape of the protein peak 
being slightly more relevant to that of activity (Figure 59). The NaCl wash fractions also had 
a significant amount of carbohydrate and protein within their active peak (Figure 60), 
suggesting the second peak may be caused by a carbohydrate-protein complex. 
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Figure 58. ELISA of post-Sephacryl S500 HR column chromatography fractions, with NaCl wash 
data, for the second column run. Column was eluted with 483 mL of water, and then washed with 0.15 
M NaCl solution. Eluted fractions were applied to Raw cells in 96-well plates at a 50% dilution. LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 59. TNF-α production of the second Sephacryl S500 HR column run in relation to carbohydrate 
and protein content. Eluted fractions were applied to Raw cells in 96-well plates at a 50% dilution. 
LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 60. TNF-α production of the second Sephacryl S500 HR column NaCl wash in relation to 
carbohydrate and protein content. Eluted fractions were applied to Raw cells in 96-well plates at a 50% 
dilution. LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). 
Error bars represent SEM. 
 
Similar trends were observed in the third run of the Sephacryl S500 HR column. 
Significant activity was seen between elution volumes of 273-343 mL. The top three 
fractions were observed between 283-303 mL and contained the highest carbohydrate and 
protein contents. Again, the shape of the active peak corresponded with the shape of the 
protein peak (Figure 61). The NaCl wash of the column showed a significant peak of activity 
between 766-826 mL. This appeared to closely correlate with the carbohydrate content, 
however, a spike in protein was also observed in the most active fraction (Figure 62).  
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Figure 61. TNF-α production of the third Sephacryl S500 HR column run in relation to carbohydrate 
and protein content. Eluted fractions were applied to Raw cells in 96-well plates at a 50% dilution. 
LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 62. TNF-α production of the third Sephacryl s500 HR column NaCl wash in relation to 
carbohydrate and protein content. Eluted fractions were applied to Raw cells in 96-well plates at a 50% 
dilution. LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). 
Error bars represent SEM. 
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A fourth run was performed on the Sephacryl S500 HR column to increase the amount 
of post column fraction for subsequent analysis. Activity peaks were observed between 273-
323 mL during the water run (Figure 63), and 766-826 mL for the NaCl run (Figure 64). Of 
these, the top three fractions occurred between 283-303 mL in the water run, and 776-806 mL 
in the NaCl run. The top three fractions of each water run were pooled, lyophilized, and 
subjected to further chemical and biological characterization. The top two fractions of each 
NaCl run were also pooled, dialyzed, lyophilized and kept for future characterization.  
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Figure 63. TNF-α production of the fourth Sephacryl S500 HR column run. Raw 264.7 cells were 
plated at a density of 100,000 cells/well. Eluted fractions were applied to wells at a 50% dilution. LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
 
109 
 
7 4 0 7 6 0 7 8 0 8 0 0 8 2 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
V o l u m e  ( m L )
T
N
F
-
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
L
)
 
Figure 64. TNF-α production of the fourth Sephacryl S500 HR column NaCl wash. Raw 264.7 cells 
were plated at a density of 100,000 cells/well. Eluted fractions were applied to wells at a 50% dilution. 
LPS was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
 
3.3.6 Enzyme Digestion 
Enzyme digestions were performed on the most active post-Sephacryl S500 HR 
fraction from the first column run. The first series of digestions were performed with lower 
doses of cellulase and amyloglucosidase, calculated from the manufacturer suggested activity 
of the enzyme relative to the carbohydrate content of the sample. A higher dose repeat was 
performed for cellulase and amyloglucosidase to observe if higher concentrations could 
remove the immuno-stimulatory activity. Immediately apparent was that cellulase stimulated 
TNF-α in its water controls, potentially masking its activity on the samples tested (Figures 65 
and 66). By subtracting the enzyme control values from the treated sample values, it was 
possible to see the effects of enzyme activity that could be masked by such stimulation. 
A PSK solution was tested alongside the post-Sephacryl fraction as a positive control. 
PSK activity was completely removed by proteinase-K digestion at both treatment 
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concentrations used (Figure 67). Cellulase was also able to reduce PSK activity in a dose-
dependent manner, completely removing activity in the 10 and 30 unit doses (Figure 67 and 
68). Amyloglucosidase was only effective at its highest tested dose of 30 units (Figure 68).  
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Figure 65. Effect of proteinase K, cellulose and amyloglucosidase on the immuno-stimulatory activity 
of PSK. Two-hundred and fifty microliters of PSK solution was treated with either 1 or 3 units of 
cellulase, 0.3 or 1 unit of amyloglucosidase, or 3 or 15 units of proteinase-K. Raw 264.7 cells were 
plated at a density of 100,000 cells/well. Eluted fractions were applied to wells at a 1/4 dilution. LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 66. Effect of cellulase, amyloglucosidase and proteinase-K on the immuno-stimulatory activity 
of bioactive compound(s) from P. aurea. Two-hundred and fifty microliters of post-sephacryl S500 
fraction was treated with either 1 or 3 units of cellulase, 0.3 or 1 unit of amyloglucosidase, or 3 or 15 
units of proteinase-K. Raw 264.7 cells were plated at a density of 100,000 cells/well. Eluted fractions 
were applied to wells at a 1/4 dilution. LPS was treated at a well concentration of 500 ng/mL as a 
positive control (data not shown). Error bars represent SEM. 
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Figure 67. Effect of cellulase, amyloglucosidase and proteinase-K, on the immuno-stimulatory activity 
of PSK. Two-hundred and fifty microliters of PSK solution was treated with either 1 or 3 units of 
cellulase, 0.3 or 1 unit of amyloglucosidase, or 3 or 15 units of proteinase-K. Raw 264.7 cells were 
plated at a density of 100,000 cells/well. Eluted fractions were applied to wells at a 1/4 dilution. LPS 
was treated at a well concentration of 500 ng/mL as a positive control (data not shown). Error bars 
represent SEM. 
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Figure 68. Effect of cellulase or amyloglucosidase on the immuno-stimulatory activity of PSK. Two-
hundred and fifty microliters of PSK solution was treated with either 10 or 30 units of cellulase or 
amyloglucosidase. Raw 264.7 cells were plated at a density of 100,000 cells/well. Eluted fractions 
were applied to wells at a 1/4 dilution. LPS was treated at a well concentration of 500 ng/mL as a 
positive control (data not shown). Error bars represent SEM. 
 
The post-Sephacryl S500 HR fraction was tested under the same conditions as the 
PSK control. The most effective enzyme in reducing activity was proteinase-K, showing 
reductions in activity at both dose levels (Figure 69). This would suggest that activity may be 
protein-dependent. A slight reduction in activity was seen with cellulase digestion at a 3 unit 
dose (Figure 69), becoming more pronounced in the higher doses of 10 and 30 units (Figure 
70). This suggests the presence of β-glucans, which are also contributing to the activity. 
Amyloglucosidase was not observed to significantly affect activity in any dose level tested 
(Figures 69 and 70). As activity can be reduced to relatively low levels by both proteinase-K 
and cellulase, it is suspected that the bioactive compound could be a β-glucan-protein 
complex, requiring both components to be functional for optimum activity.  
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Figure 69. Effect of cellulase, amyloglucosidase and proteinase-K on the immuno-stimulatory 
compound(s) from P. aurea. Two-hundred and fifty microliters of post-sephacryl fraction was treated 
with either 1 or 3 units of cellulase, 0.3 or 1 unit of amyloglucosidase, or 3 or 15 units of proteinase-K. 
Raw 264.7 cells were plated at a density of 100,000 cells/well. Eluted fractions were applied to wells at 
a 1/4 dilution. LPS was treated at a well concentration of 500 ng/mL as a positive control (data not 
shown). Error bars represent SEM. 
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Figure 70. Effect of cellulase or amyloglucosidase on the immuno-stimulatory compound(s) from P. 
aurea. Two-hundred and fifty microliters of post-sephacryl fraction was treated with either 10 or 30 
units of cellulase or amyloglucosidase. Raw 264.7 cells were plated at a density of 100,000 cells/well. 
Eluted fractions were applied to wells at a 1/4 dilution. LPS was treated at a well concentration of 500 
ng/mL as a positive control (data not shown). Error bars represent SEM. 
 
3.3.7 Mouse Cytokine Array/Chemokine Array 32-Plex 
Results of cytokine analysis following treatment onto Raw 264.7 cells were obtained 
from Eve Technologies Corporation (Calgary). As seen in Table 5, the post-Sephacryl 
fractions were able to stimulate the production of many cytokines. It appears that the 
strongest stimulation was seen in pro-inflammatory cytokines, suggesting that the 
compounds stimulate the innate immune system. TNF-α production was again confirmed and 
suggests an inflammatory response, as it is known to be an immune cell regulator affiliated 
with systemic inflammation126. The strongest stimulation was seen in the macrophage 
inflammatory proteins (MIP-1α, MIP-1β, and MIP-2). These are known chemotactic agents 
in the recruitment and activation of leukocytes and hematopoietic cells in response to injury 
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or infection127–129. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were also induced and are involved in the 
proliferation and maturation of neutrophils, macrophages, and eosinophils130. Stimulation of 
interferon gamma-induced protein 10 (IP-10) is promising, as this cytokine has been 
affiliated with antitumor activity due to its antiangiogenic effects131. It is also a 
chemoattractant that promotes the adhesion of T cells to endothelial cells132. Monocyte 
chemoattractant protein 1 (MCP-1) is another recruitment protein, attracting monocytes, 
memory T cells and dendritic cells to sites of inflammation133,134, supporting the theory of 
pro-inflammatory activity in the tested compounds. Interleukin 6 (IL-6) was also moderately 
stimulated and is involved in acute phase immune response, showing pro-inflammatory 
activities135. While other cytokines were mildly induced, the strength of the ones described 
suggest that P. aurea contains compounds that stimulate the innate immune system. 
Purification attempts appear to have isolated pro-inflammatory compounds. 
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3.4 Discussion 
The initial purification attempts on P. aurea hot water extracts appear to show the 
presence of multiple bioactive compounds. While primarily immuno-stimulatory, this extract 
was also found to contain cytotoxic compounds, which could be separated using Sephadex 
LH20 size exclusion method directly from the crude extract. Based on the protein content of 
the cytotoxic fraction, one would suspect the compound is primarily protein based and larger 
than 4000 kDa due to its early elution from the LH-20 columns. By proceeding with the 
Sevag method, a known deproteinating step125,136,137, the cytotoxic activity was eliminated, 
supporting the idea that the anti-proliferative compound found in the crude extract is protein-
based. Since the choice was made to pursue the immuno-stimulatory activity in the extract, 
the anti-proliferative compound(s) was not further studied and may be a target for future 
characterization. Subjecting the immuno-stimulatory fractions to heat did not eliminate its 
activity, suggesting that its active compound(s) may not be completely protein dependent. 
Due to this, and the high carbohydrate content of the immuno-stimulatory fractions, the 
switch to a more carbohydrate targeted approach was taken. 
The purification scheme used has been successfully applied to the isolation of 
bioactive polysaccharides from mushrooms. Following hot water extraction, crude extracts 
were subjected to deproteination, such as Sevag method, and then applied to various 
chromatography columns to separate the polysaccharides into homogenous fractions. This is 
done commonly with ion-exchange chromatography, followed by size exclusion 
methods84,137,138. Following Sevag method deproteinization, the P. aurea crude 
polysaccharides were then applied to an ion-exchange media equilibrated in water. The use 
of water as a buffer has been successful used in the separation of antitumor 
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polysaccharides138. By using the batch method in experiments, difficulties arising from 
variances in volume due to the ionic strength of the elution buffer were avoided. It was also 
easier to upscale experiments, allowing for larger volumes, and thus larger quantities of 
crude polysaccharides to be processed at a time. As yellowing of the media was observed, it 
was suspected that not all of the bound sample was retrieved with elution. This may have 
affected the binding of active compounds in subsequent experiments, as media was re-
equilibrated in water and re-used. The effects of this may be mitigated by the two-stage 
approach used, as the secondary media bed would offer more binding opportunity. As yields 
were observed to slightly decrease when the bed volume to sample ratio was increased, it is 
not likely that the binding capacity of the media was exceeded, but that the media was 
perhaps trapping compounds following elution. Even with 2 M NaCl in elution buffer, the 
yields were not increased, suggesting the compound may have an affinity for the media. 
The purified sample collected from DEAE media was not observed to show any 
increase in activity relative to the starting material. This suggests that the DEAE ion-
exchange chromatography step may not be effective in purifying the bioactive compound(s) 
so much as portioning the starting material. The post-Sevag extract may be relatively pure, 
and there may be little or no contaminants to be removed with ion-exchange 
chromatography. Upon proceeding into size-exclusion chromatography, only one activity 
peak was observed, suggesting one active compound, or a group of similarly sized 
compounds was retrieved following elution from the DEAE media. Again, binding to the 
media was observed with the Sephacryl S500 column, as a secondary front of activity was 
collected with the NaCl wash. It is unclear if this is a portion of the same compound or a 
separate compound all together. As all active fractions were observed to have both 
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carbohydrate and protein, it is suspected that the activity may be linked to a carbohydrate-
protein complex. The phenol-sulfuric carbohydrate method adopted for the later experiments 
was observed to be more variable than the assay kit that was initially used. Triplicates were 
not observed to consistently change colour, causing larger standard error values. However, it 
did allow for a general determination of which fractions contained the most carbohydrate. 
Enzyme digestion of the purified sample has given some hints as to what components 
are required for its immuno-stimulatory activity. The dramatic decrease with proteinase-K 
digestion suggested that protein component is important for its activity. As the samples were 
deproteinated during the chloroform shakes of the Sevag method, it is believed that protein in 
the sample may be covalently bound to a carbohydrate, which may have protected it from 
denaturation. The decrease in activity with cellulase digestion also supports the idea of 
carbohydrate being a contributor to its activity. As cellulase cleaves β-linkages, and due to 
the common presence of β-glucans in mushrooms, it is suspected that the bioactive 
compound(s) has polysaccharide component composed of β-glucan. Indeed, recent β-glucan 
assay experiments in Dr. Lee’s laboratory on the purified sample from P. aurea show that it 
has glucans consisting of 86% β-glucan and 14% α-glucan. Since both Proteinase K and 
cellulase significantly decrease its activity, it can be concluded that both the protein and 
carbohydrate components are required for the immuno-stimulatory activity.  
The pro-inflammatory stimulation could be another sign of β-glucan presence. β-
glucans forming helical structures have been found to stimulate TNF-α production in 
macrophages. The conformation of these polysaccharides has been proven to be a relevant 
part of their activity139. The degree of side branching from the main chain of the carbohydrate 
was seen to affect the conformation and thus activity. β-glucans with a higher degree of side 
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branching tend to form tighter helical structures, and were therefore more active33,139. It is 
thought that these glucans are recognized and bound by Dectin-1 receptors, which then 
initiate an innate immune response. Downstream effects include the release of cytokines IL-
12, IL-6, IL-10, and TNF-α, ultimately leading to phagocytosis and a pro-inflammatory 
response33. As β-glucans do not naturally occur in the human body, it is generally thought 
that they are the body’s recognition molecule for fungal and bacterial contaminants. The 
response is therefore the body’s natural way of dealing with fungal and bacterial infection33. 
Further detailed structural characterization is required to determine the exact identity 
of the bioactive molecule responsible for immuno-stimulatory activity. While the evidence 
points to the presence of protein and β-glucans, results from structural analysis have not been 
obtained at this time. Once the structure is identified, a more specific purification approach 
can be made. This could eliminate unnecessary steps, as well as improve product yields.  
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Chapter 4: General Discussion 
4.1 Introduction 
The primary goal of this study is to initiate exploration of some wild mushrooms and 
lichens native to northern British Columbia for bioactivities that are relevant to anticancer 
therapies. The first objective involved collection, identification, extraction and screening of 
crude extracts from four mushrooms and two lichens for growth-inhibitory and immuno-
stimulatory activities. The second objective involved the purification and characterization of 
an immuno-stimulatory compound from a selected mushroom species. 
The results from this study show that indeed wild mushrooms and lichens of northern 
BC do contain growth-inhibitory and immuno-stimulatory compounds. This study has 
revealed many new findings in regards to fungi and lichens from northern BC which is 
primarily due to the lack of previous study. This exposes a need for more research into the 
bioactivity of natural products from BC. It would appear that the growth-inhibitory effects 
arise from the fungi’s own defense mechanisms, where production of such adverse 
compounds would be beneficial to deter predation, whereas the immunological responses 
arise from the host’s defense mechanisms, where the ability to detect fungal infectants would 
benefit its own survival. One could assume that since the human body evolved in a world of 
natural compounds, it is naturally geared to identify these compounds and elicit a response. 
Due to this, one may argue that we are more likely to find bioactive compounds from natural 
sources, rather than synthetically produced compounds with no natural origin. It is the body’s 
own defenses that have caused the immunological responses seen from mushroom 
compounds, and by boosting its defenses, a wide array of illnesses can be affected. The 
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mushroom compounds basically prime the immune system, which can then target other 
pathogens, leaving them strong candidates for overall health promotion140.  
4.2 Sample Identification and Screening for Growth-Inhibitory and Immuno-
stimulatory Activities 
Sample #1 was identified as Hericium coralloides. While not widely studied, this 
species is related to the well-known Hericium erinaceus, which is commonly used in 
traditional Chinese medicine. Results show that this mushroom contains mild immuno-
stimulatory activity in regards to TNF-α production. This was primarily seen in hot water 
extracts. It was not observed to show any growth-inhibitory effects against HeLa cells. 
Interestingly, mild growth-stimulatory activity was initially observed, but this effect was not 
persistent over time. Due to its relation to a well characterized species and its unexpected 
growth-stimulatory activity, this mushroom warrants further investigation.  
Sample # 2 was identified as Hydnellum diabolus. Species from this genus have not 
been well characterized in terms of bioactivity, being primarily studied for their morphology, 
taxonomy, and conservation141–146. One study had isolated an anticoagulant, atromentin, from 
this species101, but otherwise it remains unstudied for other biological effects. Growth-
inhibitory effects were observed in the ethanol and hot water extracts of Hydnellum diabolus. 
In addition, mild stimulation of TNF-α was seen in the hot water extract. To our knowledge, 
this study is the first to report such bioactivities from this species. Future investigations such 
as purification and identification of its bioactive constituents are clearly warranted. 
Sample #3 was identified as Phaeolepiota aurea. This monotypic genus has not been 
previously studied for immunological or growth-inhibitory effects. One study had previously 
isolated two lectins from this mushroom108, however no further attempts to derive natural 
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products have been made. The cytotoxicity MTT assays show growth-inhibitory activity in 
the ethanol and hot water extracts of this mushroom. A strong stimulation of TNF-α 
production was seen in the methanol and hot water extracts, with hot water extracts showing 
slightly stronger activity. These are novel findings for this species, and as such, an attempt 
was made to isolate the immuno-stimulatory compound from its hot water extract. The work 
of this study is described in Chapter 3 of this thesis. 
Sample #4 was identified as Laetiporus sp.. Some species within this genus are prized 
as food and have been used in traditional medicine. Laetiporus sulphureus is particularly well 
characterized for its bioactivity109–113,147,148. Growth-inhibitory effects were found in the 
ethanol, methanol, and hot water extracts, and strong stimulation of TNF-α production was 
observed in the methanol and hot water extracts of this specimen. These findings support 
previously identified bioactivity109,112,147 within this genus; however, a confirmed species 
identity is needed to proceed with further analysis of this specimen. 
Samples #5 and #6 were identified as Letharia vulpina and Vulpicida canadensis. As 
these lichen species are known to naturally occur together, both have been similarly studied 
and are known to contain vulpinic acid115,116,118–120. The ethanol extracts of both species were 
found to show growth-inhibitory activity. Stimulation of TNF-α production was seen in the 
hot water extract of L. vulpina and the methanol extract of V. canadensis. While the cytotoxic 
activity has already been reported117,118,120, it appears that the immuno-stimulatory activity is 
a novel finding for these species. As such, these species could be targets for further 
purification, identification and characterization of the responsible compounds.  
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4.3 Purification and Characterization of an Immuno-Stimulatory Compound from 
Phaeolepiota aurea. 
Multiple experiments show that the crude extracts of P. aurea exhibited more than 
one bioactivity. The hot water extract was shown to contain both cytotoxic and immuno-
stimulatory compounds. Results show that the cytotoxic compound(s) can be separated using 
size exclusion chromatography and are thought to be primarily protein in composition. 
Immuno-stimulatory activity appeared to correlate with the carbohydrate and protein content 
seen in the bioactive fractions. As the immuno-stimulatory activity was not completely 
removed with heat, carbohydrates were thought to be a major component of the immuno-
stimulatory compound(s) and a more polysaccharide targeted approach was adopted for 
subsequent purification steps. Cytotoxic activity exhibited by a protein component was first 
removed from the crude extracts with deproteination steps (Sevag method), and the crude 
polysaccharide mixture was subjected to ion-exchange and high-resolution size-exclusion 
chromatography. While immuno-stimulatory activity was not seen to significantly increase 
with purification using DEAE ion exchange chromatography, the activity was not lost and 
remained similar to that of the crude polysaccharide material. It is possible that the activity 
may be arising from a population of polysaccharide compounds, and purification attempts are 
just sub-fractionating them. The compound may also be relatively pure following 
deproteination, becoming more dilute with each purification attempt as material is being lost 
to media binding. Once the exact structure of the bioactive compound is known, a more 
direct purification scheme can be determined, which can improve the yields obtained from 
crude mixtures. 
126 
 
The immuno-stimulatory compound purified from the last step of chromatography 
Sephacryl S-500 appears to be made up of a polysaccharide-protein complex. The post-
Sephacryl S-500 column fractions showing the strongest activity were also the ones showing 
the highest carbohydrate and protein concentrations. As the immuno-stimulatory activity 
could be dramatically reduced with the use of proteinase-K and cellulase, it is concluded that 
both protein and β-glucans are responsible for the activity. Indeed, a recent study 
(unpublished) in Dr. Lee’s laboratory show that the purified compound has 22% w/w of 
glucans in which 86% are β–glucans and 14% are α–glucans. Based on the fact that the 
deproteination Sevag method was used during purification and the results from proteinase-K 
and cellulase enzyme experiments, it is likely the immuno-stimulatory compound is a 
polysaccharide-protein complex linked by N- or/and O-linked glycosidic bonds Future 
studies are clearly required to corroborate this. 
The cytokine and chemokine analyses support the conclusion that the compound of 
interest is a stimulant of the innate immune system. The strongest stimulation was seen in 
cytokines affiliated with a pro-inflammatory response and leukocyte recruitment. The 
compound stimulates the host into an immunological response used to defend against 
infection. This correlates to the response seen from β-glucans, which are suggested to be the 
immune system’s fungal recognition molecule32. This further supports the notion that the 
immuno-stimulatory compound contains β-glucan. 
4.4 Final Conclusions and Future Directions 
The tested wild mushrooms and lichens of British Columbia have proven themselves 
to be bio-factories of immuno-stimulatory and growth-inhibitory compounds. Due to limited 
studies on the bioactivities of forest fungi worldwide, many novel bioactivities were found in 
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the fungal species native to BC. This shows a need for further study into naturally occurring 
compounds found in the wild mushrooms of western culture. 
Attempts to purify active compounds from the hot water extracts of P. aurea found 
the presence of multiple bioactive compounds. Immuno-stimulatory activity was linked to β-
glucan and protein within the final purified sample. It is believed that the immuno-
stimulatory compound is composed of polysaccharide-protein complex in which the 
polysaccharide component contains β–glucan. The compound was found to stimulate the 
innate immune system and caused the release of pro-inflammatory cytokines. 
Future studies must be undertaken to elucidate the structure of the immuno-
stimulatory compound. Monosaccharide analysis can be performed with the use of gas 
chromatography-mass spectrometry (GC-MS) to determine the monosaccharide composition 
and their linkages in the polysaccharide component of the compound49,149–151. Due to the 
presence of protein in the purified sample, experiments must be undertaken to determine if it 
is covalently linked to the polysaccharide. A β-elimination assay will aid in identifying o-
linked glycans152, while the use of enzyme N-glycosidase F (PNGase F) can determine the 
presence of N-linked glycans153. By identifying the active components of the compound, a 
more targeted isolation scheme may be determined. Once the active compound is purified to 
homogeneity, nuclear magnetic resonance (NMR) analysis can then be performed to 
determine its complete structure84,154–159. 
Screening of the 6 fungal species from British Columbia has found numerous active 
extracts to pursue. As many of the activities observed are novel findings for their species, 
purification of any of these active fractions may lead to the identification of novel bioactive 
compounds. These may be of use in pharmacological or natural therapies and warrant future 
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investigation. Purification attempts have led to the partial identification of an immuno-
stimulatory compound from P. aurea, which was found to stimulate the innate immune 
system. Due to the immuno-boosting properties, this compound, once identified, can be used 
in the treatment of a variety of ailments, including cancer, by stimulating the body to defend 
itself. This is the method of action of many anticancer mushroom compounds in use and 
clinical trials today84,140,160. 
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Appendix 
A1. DNA Consensus Sequences 
*Consensus sequences were produced by Dr Keith Egger 
Hericium coralloides  
GAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCCCCTTGG
TATTCCGAGGGGCACGCCTGTTCGAGTGTCGTGAAATTCTCAACTCARTCCTCTT
GTTATGAGAGGGCTGGGCTTGGACTTGGAGGTCTTGCCGGTGGTTCCTTCGGGAC
CGTCGGCTCCTCTTGAATGCATGAGTGGATCCCTTTTTGTAGGGTTTGCCCTTGGT
GTGATAATTATCTAYGCCGCGGGTAGCCTTGCGCGCTGGTCTGCTTCTAACCGTC
CTTCGGGACATGTTTTTCATCTCAACTTGACCTCGAATCAGGCGGGACTACCCGC
TGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGATTCCCCTA
GTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTAAAATCTGGCGGTCTTCGGC
CGTCCGAGTTGTAGTCTGGAGAAGTGCTTTCCGCGCTGGACCGTGTACAAGTCTC
CTGGAATGGAGC 
Hydnellum diabolus 
GAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAaTCTTTGAA
CGCACCTTGCGCTCCTTGGTATTccgaggagcaTGCCTGTTTGAGTGTCATGAAATTCT
CAACTGCTTTGGCATTTTTTGTTCAAAGTGAAGTTGGACTTTGGAGGGTTTGCTG
GCGTGTTCGGCTCCTCCCAAAAGCATAAAGCCTCTTTTCTTGGTAGATCTTGGCG
GAAAAGTATCTTCGACGTGATAATCATCTACGTTGTGGAGAAAGCCTTGAGCAA
AGAGCCGTTCTTTGTCTTTGACAAGGAAAGGCTTCTTCTACTGGGGTGGCTCCAC
GAGGGTTACACCTCACTTGACCAATTCGACCTCAAATCAGGCAGGACTACCCGC
TGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGATTCCCCTA
GTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTGAAATCTGGCGTGCCCTTGG
CCGTCCGAGTTGTAGTCTGGAGAAGCGTCTTCCGTGCTGGACCATGTACAAGTCC
CTTGGAACAGGGC 
Phaeolepiota aurea 
GAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA
ACGCACCTTGCGCTCCTTGGTATTCCGAGGAGCATGCCTGTTTGAGTGTCATTAA
ATTCTCAACCTTTCCAAGTTTTATTACCTGGTCAGGCTTGGATTTGGGGGTTGCAG
GTTTCTTTCATGAAGTCAGCTCCTCTTAAATACATTAGCGGAACCTTTTTGTGGAC
TGTCAAATGGTGTGATAATTATCTACACTATTGTACGCTGCAATCTTATAGGGCT
TCAGCTTCTAACTGTCCATTGACTTGGACAATTCTTGACCATTTGACCTCAAATCA
GGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTA
ACAAGGATTCCCCTAGTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTAAAAT
CTGGCGGTCTTTGGCTGTCCGAGTTGTAATCTAGAGAAGTGTTATCCGCGCTGGA
CCGTGTACAAGTCTCCTGGAATGGAGC 
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Laetiporus sp. 
*Sample Contaminated* 
Letharia vulpina 
GAaAtGcgATaagTAATGTgAATtGCAGAAtTCAGTgAATCATcGAATcTTTGAACGCA
CAtTGCgCCCcTcgGTATTCCGGGGGGCAtgCcTGTTcGAGCGTCATTGCACCCCTCA
AGcGTAGctTGGTATTGGGTCTTcGCCCCCGCGgcGtGCCcGAAAatCAgtggcggTccGGT
GtGActTtAagcgTAGTAAATTtTcGTccgcTTTGAAAGTTcGcgCcGTgcCcGgCCAGaCaAC
CCCccctYTATTTCAATAaTTGaCCTcGGaTCagGtagggAtACCCGctGAAcTTAAGCATA
TCAATAAgCGGAGGAAAAgAAACCaWcaGGGaTTGCCTCAgtAACGGCgAgtGAagcG
GCATCAgCTCAAATTTGAAATCTGGCCCTTTCggGGtCCgAGTTGtAATTTgtAgAgAG
TGTttCggGGGAgAccaCggtCTaagtCCattGgAACATGGc 
Vulpicida canadensis 
GAAATGCGATAACTAATGTGAATTGCAGAATTCAGTGAATCATCGAGTCTTTGA
ACGCACATTGCGCCCCTCGGTATTCCGGGGGGCATGCCTGTTCGAGCGTCATTAT
ACCCTTCAAGCGTAGCTTGGTATTGGGCCTCGCCCCCACGGCGTGCCCGAAAAG
CAGTGGCGGTCCGGGGCGACTTTGAGCGTAGTAAAATCATCCCGCTTTGAAAGC
TCGCCTCGCGGCCGGCCAGACAACCCCATTCATTCTATACATTGACCTCGGATCA
GGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACC
AACAGGGATTGCCTCAGTAACGGCGAGTGAAGCGGCAACAGCTCAAATTTGAAA
TCTGGCCCCGTCGGGGTCCGAGTTGTAATTTGTAGAGAGTGCTTCGGGTGAGACC
GCGGTCTAAGTCCATTGGAACATGGC 
